

CTAD Alzheimer 2021

Clinical Trials on Alzheimer's Disease



ONSITE



ONLINE

November 9-12, 2021
Boston, USA

Montpellier '08 / Las Vegas '09 / Toulouse '10 / San Diego '11
Monte Carlo '12 / San Diego '13 / Philadelphia '14 / Barcelona '15
San Diego '16 / Boston '17 / Barcelona '18 / San Diego '19 / Boston '20 (digital)

www.ctad-alzheimer.com

Email: ctad@ant-congres.com





SUMMARY

Organizing & Scientific Committees	3
Lifetime Achievement Award	4
Keynotes	5
Preliminary program	7
Live program onsite in Boston & Livestreamed on the digital platform	7
On demand scientific program presented on the digital platform	31
Onsite Poster presentations	20
Poster presented remotely	39



CTAD Organizing Committee

Jacques Touchon MD, PhD
University of Montpellier
France

Paul Aisen MD
Alzheimer's
Therapeutic Research Institute (ATRI)
University of Southern California (USC),
San Diego, USA

Bruno Vellas MD, PhD
University
Hospital of Toulouse
France

Mike Weiner MD
University of California
San Francisco (UCSF)
USA

CTAD Scientific Committee

Susan ABUSHAKRA (San Francisco, USA); Paul AISEN (San Diego, USA); Rebecca E. AMARIGLIO (Boston, USA); Sandrine ANDRIEU (Toulouse, France); Randall J. BATEMAN (St. Louis, USA); Kaj BLENNOW (Molndal, Sweden); Merce BOADA (Barcelona, Spain); Marc CANTILLON (Livingston, USA); Maria CARRILLO (Chicago, USA); Suzanne CRAFT (Winston-Salem, USA); Steven DEKOSKY (Miami, USA); Rachelle DOODY (Basel, Switzerland); Bruno DUBOIS (Paris, France); Howard FELDMAN (San Diego, USA); Nick FOX (London, UK); Giovanni B. FRISONI (Brescia, Italy); Serge GAUTHIER (Montreal, Canada); Michael GRUNDMANN (San Diego, USA); Harald HAMPEL (Woodcliff Lake, USA); Oskar HANSSON (Lund, Sweden); Tobias HARTMANN (Homburg, Germany); Takeshi IWATSUBO (Tokyo, Japan); Frank JESSEN (Cologne, Germany); Ara KHACHATURIAN (Washington DC, USA); Zaven KHACHATURIAN (Washington DC, USA); Yan LI (St. Louis, USA); Jorge J. LLIBRE GUERRA (St. Louis, USA); Constantine G. LYKETSOS (Baltimore, USA); Gad A. MARSHALL (Boston, USA); José Luis MOLINUEVO (Barcelona, Spain); Ronald PETERSEN (Minnesota, USA); Craig W. RITCHIE (Edinburgh, UK); Robert RISSMAN (San Diego, USA); Marwan SABBAGH (Las Vegas USA); Stephen SALLOWAY (Providence, USA); Rachel SCHINDLER (New York, USA); Philip SCHELTENS (Amsterdam, NL); Lon SCHNEIDER (Los Angeles, USA); Eric SIEMERS (Philadelphia, USA); Yong SHEN (Heife, China); Jiong SHI (Las Vegas, USA); Reisa SPERLING (Boston, USA); Yaakov STERN (New York, USA); Jacques TOUCHON (Montpellier, France); Christopher H. VAN DYCK (New Haven, USA); Bruno VELLAS (Toulouse, France); Michael W. WEINER (San Francisco, USA); Bengt WINBLAD (Stockholm, Sweden); Jin-Tai YU (Shanghai, China)

CTAD 2021 Lifetime Achievement Award



This year the Lifetime Achievement Award in Alzheimer's Disease Therapeutic Research is awarded to Ron Petersen, MD, Ph.D., in recognition for his extensive contributions to the advancement of AD clinical trials.

Ronald C. Petersen, MD, PhD - Professor of Neurology and Director of the Mayo Alzheimer's Disease Research Center, Mayo Clinic, Rochester, MN (USA).

Dr. Ronald C. Petersen received a Ph.D. from the University of Minnesota and graduated from Mayo Medical School in 1980. He completed an internship in Medicine at Stanford University Medical Center and returned to the Mayo Clinic to complete a residency in Neurology. That was followed by a fellowship in Behavioral Neurology at Harvard University Medical School/Beth Israel Hospital in Boston, Massachusetts. Dr. Petersen was named the Cora Kanow Professor of Alzheimer's Disease Research and Mayo Clinic Distinguished Investigator in 2011. He is currently the Director of the Mayo Alzheimer's Disease Research Center and the Mayo Clinic Study of Aging and has authored over 1000 peer-reviewed articles on memory disorders, aging, and Alzheimer's disease. Dr. Petersen has received the 2004 MetLife Award for Medical Research in Alzheimer's Disease and the 2005 Potamkin Prize for Research in Picks, Alzheimer's and Related Disorders of the American Academy of Neurology. In 2012 he received the Khachaturian Award and the Henry Wisniewski Lifetime Achievement Award in 2013 from the Alzheimer's Association. In 2011 he was appointed by the Secretary of Health and Human Services to serve as the Chair of the Advisory Committee on Research, Care and Services for the National Alzheimer's Disease Plan.

Keynotes



“Anti-Tau Drug Development for Alzheimer’s Disease and Other Tauopathies”

Adam Boxer, MD, PhD

Endowed Professor in Memory and Aging, University of California, San Francisco (UCSF), USA

Dr. Boxer directs UCSF’s Neurosciences Clinical Research Unit and the Alzheimer’s Disease and Frontotemporal Degeneration (FTD) Clinical Trials Program at the UCSF Memory and Aging Center. Dr. Boxer’s research is focused on developing new treatments and biomarkers for neurodegenerative diseases, particularly those involving tau and TDP-43. Dr. Boxer received his medical and doctorate degrees as part of the NIH-funded Medical Scientist Training Program at New York University Medical Center. He completed an internship in Internal Medicine at California Pacific Medical Center, a residency in Neurology at Stanford University Medical Center, followed by a fellowship in behavioral neurology at UCSF. He is the principal investigator (PI) of the **Advancing Research and Treatment for FTLD (ARTFL)** Rare Disease Clinical Research Consortium, a collaborative project funded by the National Institutes of Health to create an 18-center North American research network to support the development of new therapies for FTLD. He also leads the **Four Repeat Tauopathy Neuroimaging Initiative (4RTNI)**, a multicenter, longitudinal tau PET and biomarker study focused on PSP and CBD.



“Vascular Risk Factors and Alzheimer’s Disease: Implications for Clinical Trials”

Cynthia Carlsson, MD, MS

Professor in Alzheimer’s Disease, Division of Geriatrics and Gerontology, University of Wisconsin, Madison, WI (USA)

Dr. Carlsson is a geriatrician at the William S. Middleton Memorial Veterans Hospital in Madison, Wisconsin, where she treats veterans with dementia and memory issues. She is the Clinical Core leader and a co-leader for the Biomarker Core in the Wisconsin ADRC. She also serves as director of the Wisconsin Alzheimer’s Institute. Dr. Carlsson’s research focuses on the effects of vascular risk factors and their treatments on cognition and biomarkers for Alzheimer’s disease in persons at risk for dementia. Vascular risk factors in midlife, such as high cholesterol and elevated blood pressure, have been associated with an increased risk of developing Alzheimer’s disease decades later. It is unknown, however, whether treating vascular risk factors will reduce the risk of dementia.

Keynotes



“Biostatistics in Alzheimer’s Disease Therapeutic Trials: A Future of Convergence”

Rema Raman, PhD

Professor of Neurology, Keck School of Medicine, University of Southern California and Director of Biostatistics at USC Alzheimer Therapeutic Research Institute, San Diego, CA (USA)

Rema Raman is a Professor of Neurology at the University of Southern California (USC) and the Director of Biostatistics at USC’s Alzheimer’s Therapeutic Research Institute. She also serves as the Biostatistics Unit lead and Recruitment Unit co-lead for the National Institute of Health funded Alzheimer Clinical Trials Consortium. Dr. Raman has extensive experience as a biostatistician and clinical trialist, providing biostatistics and data management leadership and support to the design, coordination, conduct and analyses of clinical trials in Alzheimer’s disease, acute stroke, post-traumatic stress disorder, and traumatic brain injury. Her statistical research interests are in efficient clinical trial design and analysis, centralized statistical monitoring and data visualization, recruitment and retention and missing and longitudinal data analysis topics. Dr. Raman is committed to the effective teaching of biostatistics and clinical trial methodology and is the co-director of the National Institute on Aging and Alzheimer’s Association funded Institute of Methods and Protocols for Advancement of Clinical Trials in AD/DRD (IMPACT-AD).



“Therapeutic Trials in Alzheimer’s Disease: A New Hope for 2022?”

Ronald C. Petersen, MD, PhD

Professor of Neurology and Director of the Mayo Alzheimer’s Disease Research Center, Mayo Clinic, Rochester, MN (USA)

Dr. Ronald C. Petersen received a Ph.D. from the University of Minnesota and graduated from Mayo Medical School in 1980. He completed an internship in Medicine at Stanford University Medical Center and returned to the Mayo Clinic to complete a residency in Neurology. That was followed by a fellowship in Behavioral Neurology at Harvard University Medical School/Beth Israel Hospital in Boston, Massachusetts. Dr. Petersen was named the Cora Kanow Professor of Alzheimer’s Disease Research and Mayo Clinic Distinguished Investigator in 2011. He is currently the Director of the Mayo Alzheimer’s Disease Research Center and the Mayo Clinic Study of Aging and has authored over 1000 peer-reviewed articles on memory disorders, aging, and Alzheimer’s disease. Dr. Petersen has received the 2004 MetLife Award for Medical Research in Alzheimer’s Disease and the 2005 Potamkin Prize for Research in Picks, Alzheimer’s and Related Disorders of the American Academy of Neurology. In 2012 he received the Khachaturian Award and the Henry Wisniewski Lifetime Achievement Award in 2013 from the Alzheimer’s Association. In 2011 he was appointed by the Secretary of Health and Human Services to serve as the Chair of the Advisory Committee on Research, Care and Services for the National Alzheimer’s Disease Plan.



Live program onsite
in Boston


& Livestreamed
on the digital platform

Program at a glance



All times are USA Eastern Standard Time

● Tuesday, NOVEMBER 9

- 4.00 p.m. PROGRAM ONSITE in Boston & LIVESTREAMED on the digital platform 
- 4.00 p.m. Opening Ceremony and CTAD Lifetime Achievement Award
- 4.15 p.m. KEYNOTE 1: Therapeutic Trials in Alzheimer's Disease: A New Hope for 2022?
- 4.35 p.m. ROUNDTABLE 1: The FDA accelerated approval of aducanumab: a panel discussion
- 5.05 p.m. SYMPOSIUM 1: Recent advances in plasma biomarkers to improve preclinical and prodromal AD trials
- 5.45 p.m. Networking time and receptions

● Wednesday, NOVEMBER 10

- 8.00 a.m. PROGRAM ONSITE in Boston & LIVESTREAMED on the digital platform 
- 8.00 a.m. KEYNOTE 2: Anti-Tau Drug Development for AD and Other Tauopathies
- 8.20 a.m. ROUNDTABLE 2: New hope in translational research for Alzheimer drug development
- 8.50 a.m. ORAL COMMUNICATIONS
- 9.50 a.m. ROUNDTABLE 3: Digital Therapeutics for Mild Cognitive Impairment: New Pathway to Treatment
- 10.20 a.m. Coffee break and poster session
- 10.50 a.m. LATE BREAKING READOUT ROUNDTABLE 4
- 11.20 a.m. ORAL COMMUNICATIONS
- 12.05 p.m. Lunch
- 1.20 p.m. SYMPOSIUM 2: TRAILBLAZER-ALZ: Three Clinical Trials of Donanemab in Early Alzheimer's Disease
- 2.00 p.m. LATE BREAKING READOUT ROUNDTABLE 5
- 2.30 p.m. ORAL COMMUNICATIONS
- 4.00 p.m. Coffee break and poster session
- 4.30 p.m. SYMPOSIUM 3: Bringing Repurposed Drugs to Market: Challenges and Opportunities from Research to Commercialization
- 5.10 p.m. Networking time and receptions

● Thursday, NOVEMBER 11

- 8.00 a.m. ONSITE PROGRAM LIVE STREAMED to the digital platform 
- 8.00 a.m. KEYNOTE 3: Vascular Risk Factors and AD: Implications for Therapeutic Trials
- 8.20 a.m. ORAL COMMUNICATIONS
- 8.50 a.m. LATE BREAKING ORAL COMMUNICATIONS
- 9.50 a.m. Coffee break and poster session
- 10.20 a.m. LATE BREAKING ORAL COMMUNICATIONS
- 11.35 a.m. LATE-BREAKING READOUT ROUNDTABLE 6
- 12.05 p.m. Lunch
- 1.20 p.m. ORAL COMMUNICATIONS
- 2.20 p.m. KEYNOTE 4: Biostatistics in Alzheimer's Disease Therapeutic Trials: A Future of Convergence
- 2.40 p.m. ORAL COMMUNICATIONS
- 3.40 p.m. Coffee break and poster session
- 4.10 p.m. ROUNDTABLE 7: Value-Generating Exploratory Trials in Neurodegenerative Dementias
- 4.40 p.m. ORAL COMMUNICATIONS
- 5.10 p.m. Networking time and receptions

● Friday, NOVEMBER 12

- 8.00 a.m. ONSITE PROGRAM LIVE STREAMED to the digital platform 
- 8.00 a.m. SYMPOSIUM 4: Metabolomics a Biochemical Roadmap for Drug Discovery in Alzheimer's Disease
- 8.40 a.m. ORAL COMMUNICATIONS
- 9.25 a.m. LATE BREAKING ORAL COMMUNICATIONS
- 10.25 a.m. Coffee break and poster session
- 10.55 a.m. ORAL COMMUNICATIONS
- 11.55 p.m. Lunch break
- 1.00 p.m. SYMPOSIUM 5: Diversity in Alzheimer's Disease Clinical Trials
- 1.40 p.m. ORAL COMMUNICATIONS
- 3.10 p.m. Statistics workshop: re-thinking trial outcomes

● Tuesday,
NOVEMBER 9

All times are USA
Eastern Standard Time



PROGRAM ONSITE in Boston & LIVESTREAMED on the digital platform



- 4.00 p.m** **Opening Ceremony and CTAD Lifetime Achievement Award Alzheimer's Disease Therapeutic Research**
Presented to Ronald C. Petersen, MD, PhD, in recognition for his extensive contributions to the science and therapeutics of Alzheimer's Disease
Introduction by Paul Aisen, *Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, CA (USA)*, Jacques Touchon, *Montpellier University, Montpellier (France)*, Bruno Vellas, *Gerontopole, Toulouse University, Toulouse (France)*, Mike Weiner, *UCSF, San Francisco, CA (USA)*
- 4.15 p.m** **KEYNOTE 1**
Therapeutic Trials in Alzheimer's Disease: A New Hope for 2022?
Ronald C. Petersen, *Mayo Alzheimer's Disease Research Center, Mayo Clinic, Rochester, MN (USA)*
- 4.35 p.m** **ROUNDTABLE 1**
The FDA accelerated approval of aducanumab: a panel discussion
Paul Aisen, *Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, CA (USA)*, Maria Carrillo, *Alzheimer's Association, Chicago, IL (USA)*, Jason Karlawish, *University of Pennsylvania, Philadelphia, PA (USA)*, Gil Rabinovici, *University Of California San Francisco - San Francisco (USA)*
- 5.05 p.m** **SYMPOSIUM 1**
Recent advances in plasma biomarkers to improve preclinical and prodromal AD trials
Chair: **Kaj Blennow**, *University Of Gothenburg - Gothenburg (Sweden)*
Measuring Blood Based Biomarkers of Alzheimer's Disease for Clinical Trials
Jeffrey L. Dage, *Research Fellow; Eli Lilly and Company, Indianapolis, IN (USA)*
Blood plasma measures of A β , tau, and NFL species for screening and use in clinical trials of Alzheimer's disease
Randall J. Bateman, *Washington University School of Medicine, St. Louis, MO (USA)*
Diagnostic and prognostic algorithms based on blood biomarkers for use in clinical trials
Oskar Hansson, *Lund University, Lund (Sweden)*
- 5.45 p.m** **Networking time and receptions**

● Wednesday,
NOVEMBER 10

All times are USA
Eastern Standard Time



PROGRAM ONSITE in Boston & LIVESTREAMED on the digital platform



- 8.00 a.m **KEYNOTE 2**
Anti-Tau Drug Development for AD and Other Tauopathies
Adam Boxer, *University of California at San Francisco, San Francisco, CA (USA)*
- 8.20 a.m **ROUNDTABLE 2**
New hope in translational research for Alzheimer drug development
Moderator: Dennis Selkoe, *Brigham and Women's Hospital, Boston, MA (USA)*
Discussants: Kirk Daffner, *Brigham and Women's Hospital, Boston, MA (USA)* and Stephen Salloway, *Brown Medical School and Warren Alpert Medical School of Brown University, Providence, RI (USA)*
- 8.50 a.m **ORAL COMMUNICATIONS**
- 8.50 a.m **OC1 - Evoke and evoke+: two phase 3 trials investigating oral semaglutide in participants with early Alzheimer's disease**
Philip Scheltens¹, Alireza Atri^{2,3}, Howard H. Feldman⁴, Kristine Brown Frandsen⁵, Stephen C.i. Gough⁵, Peter Johannsen⁵, Filip Krag Knop⁶, Pernille Poulsen⁵, Lars Lau Raket⁵, Mary Sano⁷, Hilikka Soinenen⁸, Jeffrey Cummings⁹
¹Alzheimer Center, *Amsterdam University Medical Center, Amsterdam (The Netherlands)*, ²Banner Sun Health Research Institute - Sun City, AZ (USA), ³Brigham & Women's Hospital and Harvard Medical School - Boston, MA (USA), ⁴Harvard Medical School, Harvard University, Boston, MA - University Of California, CA (USA), ⁵Novo Nordisk A/S - Søborg (Denmark), ⁶Herlev And Gentofte Hospital, University of Copenhagen - Copenhagen (Denmark), ⁷Icahn School Of Medicine at Mount Sinai - New York, NY (USA), ⁸University of Eastern Finland - Kuopio (Finland), ⁹University Of Nevada - Las Vegas, NV (USA)
- 9.05 a.m **OC2 - Plasma GFAP is an early marker of Aβ but not tau pathology in Alzheimer's disease**
Joana Pereira¹, Shorena Janelidze², Ruben Smith², Mattsson-Carlgren Niklas², Sebastian Palmqvist², Charlotte Teunissen³, Henrik Zetterberg⁴, Erik Stomrud², Nicholas Ashton⁴, Kaj Blennow⁴, Oskar Hansson²
¹Ki, *Lund University - Lund (Sweden)*, ²Lund University - Lund (Sweden), ³Amsterdam University Medical Centers - Amsterdam (Sweden), ⁴Sahlgrenska University Hospital - Sahlgrenska University Hospital (Sweden)
- 9.20 a.m **OC3 - Phase 1 trial design for ACU193, a monoclonal antibody that selectively binds soluble Abeta oligomers**
Eric Siemers¹, Janice Hitchcock¹, Karen Sundell¹, James Senetar¹, Robert Dean¹, Jasna Jerecic², Ericka Cline², Kent Iverson², Kathleen Powell², Jerry Moore², Deven Dandekar², Chris Edgar³, Richard Manber⁴, Niccolo Fuin⁴, Russell Barton¹
¹Acumen Pharmaceuticals - Carmel (USA), ²Acumen Pharmaceuticals - Charlottesville (USA), ³Cogstate Ltd. - Melbourne (Australia), ⁴Ixico Plc - London (United Kingdom)
- 9.35 a.m **OC4 - Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (StoMP-AD): Methodology for a Randomized, Double-Blind, Placebo-Controlled Phase II Trial**
Miranda E. Orr^{1,2}, Mitzi M. Gonzales³, Valentina R. Garbarino⁴, Eduardo M. Zilli³, Ronald C. Peterson⁵, James L. Kirkland⁶, Tamara Tchkonja⁶, Nicolas Musi^{4,7}, Sudha Seshadri^{3,8}, Suzanne Craft¹
¹Wake Forest School Of Medicine, Gerontology And Geriatric Medicine, Wake Forest Alzheimer's Disease Research Center - Winston-Salem (USA), ²W. G. (Bill) Hefner VA Medical Center - Salisbury (USA), ³University Of Texas Health Science Center At San Antonio, Glenn Biggs Institute For Alzheimer's And Neurodegenerative Diseases, Department Of Neurology - San Antonio (USA), ⁴University Of Texas Health Science Center At San Antonio, Glenn Biggs Institute For Alzheimer's And Neurodegenerative Diseases, Department Of Medicine - San Antonio (USA), ⁵Mayo Clinic, Department Of Neurology, Mayo Clinic Alzheimer's Disease Research Center, The Mayo Clinic Study Of Aging - Rochester (USA), ⁶Mayo Clinic, Robert And Arlene Kogod Center On Aging - Rochester (USA), ⁷Barshop Institute for Longevity and Aging Studies and Geriatric Research, Education and Clinical Center - San Antonio (USA), ⁸Boston University School of Medicine, Department of Neurology - Boston (USA)



● Wednesday,
NOVEMBER 10

9.50 a.m

ROUNDTABLE 3

Digital Therapeutics for Mild Cognitive Impairment: New Pathway to Treatment

Murali Doraiswamy¹, Jeffrey Shuren², Rhoda Au³, James R. Williams⁴

¹Duke University - Durham, NC (USA), ²Food & Drug Administration - Silver Spring, MD (USA), ³Boston University - Boston, MA (USA), ⁴Biogen Digital Health - Cambridge, MA (USA)

10.20 a.m

Coffee break and poster session



10.50 a.m

LATE-BREAKING READOUT ROUNDTABLE 4

Phase 2 Trial of Semorinemab in Mild-to-Moderate Alzheimer's Disease (Lauriet): Topline results

Cecilia Monteiro¹, Balazs Toth¹, Kristin Wildsmith¹, Sandra Sanabria-Bohorquez¹, Flavia Brunstein¹, Andrew Madsen¹, Michael Dolton², Vidya Ramakrishnan¹, Dan Abramzon¹, Edmond Teng¹

¹Genentech, Inc. - South San Francisco (United States), ²F. Hoffmann-La Roche Ltd. - Basel (Switzerland)

11.20 a.m

ORAL COMMUNICATIONS

11.20 a.m

OC5 - Effects of the oral p38 α kinase inhibitor neflamapimod on motor function (gait) in patients with mild-to-moderate dementia with Lewy bodies (DLB)

John Alam¹, Hui-May Chu², Kelly Blackburn¹

¹Eip Pharma, Inc - Boston (USA), ²Anoixis Corporation - Natick (USA)

11.35 a.m

OC6 - Access to Alzheimer's Disease Participant Level Results Data Via Data Sharing Platforms

Rebecca Li^{1,2}, Murali Doraiswamy³, Ida Sim^{1,4}, Lon Schneider⁵

¹Vivli, Inc, Cambridge, MA (USA) ²Harvard Medical School, Center for Bioethics, Boston, MA (USA) ³Duke University School of Medicine, Durham, NC (USA) ⁴University of California, San Francisco (USCF), San Francisco, CA (USA) ⁵Keck School of Medicine of the University of Southern California, Los Angeles, CA (USA)

11.50 a.m

OC7 - Phase 2/3 trials of ATH-1017, a novel treatment for mild-to-moderate Alzheimer's disease: Updates and baseline data

Xue Hua¹, Kevin Church¹, Kai-Bin Ooi¹, Joyce Maalouf¹, William Walker¹, Charles Bernick², Sam Dickson³, Suzanne Hendrix³, Larry Ereshefsky⁴, Hans J Moebius⁵

¹Athira Pharma, Inc. - Bothell, Wa (USA), ²Department Of Neurology, University Of Washington - Seattle, Wa (USA), ³Pentara Corporation - Millcreek, Ut (USA), ⁴Follow The Molecule: Cns Consulting Llc - California (USA), ⁵Athira Pharma, Inc. - Bothell Wa (USA)

12.05 p.m

Lunch



1.20 p.m

SYMPOSIUM 2

TRAILBLAZER-ALZ: Three Clinical Trials of Donanemab in Early Alzheimer's Disease

Chair: John R. Sims, Eli Lilly & Company, Indianapolis, IN (USA)

TRAILBLAZER-ALZ study: Amyloid clearance results in a rapid and sustained reduction in plasma P-tau217 levels

John R. Sims, MD, PhD, Eli Lilly & Company, Indianapolis, IN (USA)

TRAILBLAZER-ALZ 2 Baseline Characteristics and Screening Data

Paul Solomon, PhD, Boston University Alzheimer's Disease Center, Boston, MA (USA)

TRAILBLAZER-ALZ 3 Trial Design and Rationale

Pierre Tariot, MD, Banner Alzheimer's Institute, Phoenix, AZ (USA)

● Wednesday,
NOVEMBER 10

All times are USA
Eastern Standard Time 

2.00 p.m

LATE-BREAKING READOUT ROUNDTABLE 5

Assessment of the Clinical Effects of Lecanemab, the Correlation of Plasma A β 42/40 Ratio With Changes in Brain Amyloid PET SUVr, and Safety from the Core and Open Label Extension of the Phase 2 Proof-of-Concept Study, BAN2401-G000-201, in Subjects With Early Alzheimer's Disease

Moderator: Jeffrey Cummings, *University Of Nevada - Las Vegas, NV (USA)*

Discussants : Christopher Van Dyck¹, Randall Bateman², Chad Swanson³

¹*Yale University School of Medicine - New Haven, CT (USA)*, ²*Washington University - St. Louis, MO (USA)*, ³*Eisai Inc. - Woodcliff Lake, Nj (USA)*

2.30 p.m

ORAL COMMUNICATIONS

2.30 p.m

OC8 - Results of a Phase 2 Study of AR1001 in Mild to Moderate Alzheimer's disease Patients

Philip Scheltens¹, James Rock², Vijay Hingorani², Fred Kim², Matthew Choung³

¹*Alzheimer Center at The Vu University Medical Center - Amsterdam (Netherlands)*, ²*Aribio Usa, Inc. - San Diego (USA)*, ³*Aribio, Co., Ltd. - Seongnam (Republic of Korea)*

2.45 p.m

OC9 - Binding profiles to different amyloid-beta species of lecanemab, aducanumab and gantenerumab, the three most developed antibodies for Alzheimer's disease

Lars Lannfelt¹, Malin Johannesson², Patrik Nygren², Linda Söderberg², Christer Möller²

¹*Uppsala University - Uppsala (Sweden)*, ²*Bioarctic - Stockholm (Sweden)*

3.00 p.m

OC10 - A Polymorphism Cluster at the 2q12 locus May Predict Response to Piromelatine in Patients with Mild Alzheimer's Disease

Lon Schneider¹ *University Of Southern California - Department of Psychiatry and The Behavioral Sciences, and Department of Neurology, Keck School Of Medicine, and Leonard Davis School Of Gerontology of The University of Southern California, Los Angeles, CA (USA)*

3.15 p.m

OC11 - Impact of Cocoa Flavanols and Multivitamins on Cognitive Function: Findings COSMOS-MIND

Laura Baker¹, Joann Manson^{2,3}, Stephen Rapp¹, Howard Sesso², Sarah Gaussoin¹, Sally Shumaker¹, Mark Espeland¹

¹*Wake Forest School Of Medicine - Winston-Salem (USA)*, ²*Brigham & Women's Hospital - Boston (USA)*, ³*Harvard Medical School - Boston (USA)*

3.30 p.m

OC12 - Recruiting the Innate Immune System to Treat Mild-to-Moderate Alzheimer's Disease: Short-Term, Double-Blind, Placebo-Controlled Phase II Trial Shows that GM-CSF/Sargramostim Treatment Leads to Improvements in MMSE and Blood Biomarkers of Neuropathology/Neurodegeneration (A β , Tau, and UCH-L1)

Huntington Potter¹, Jonathan Woodcock¹, Timothy Boyd², Christina Coughlan¹, John O'shaughnessy¹, Manuel Borges¹, Ashesh Thaker¹, Balaibail Raj³, Katarzyna Adamszuk⁴, David Scott⁴, Vanesa Adame¹, Paige Anton¹, Heidi Chial¹, Joseph Daniels¹, Helen Gray¹, Michelle Stocker¹, Stefan Sillau¹

¹*University Of Colorado Alzheimer's And Cognition Center - Aurora (USA)*, ²*Partner Therapeutics - Lexington (USA)*, ³*University Of South Florida - Tampa (USA)*, ⁴*Bioclinica - Princeton (USA)*

3.45 p.m

ROC9 - Performance of the PrecivityAD™ blood test in detection of brain amyloidosis in cognitively normal and cognitively impaired individuals

Suzanne Schindler¹, Kevin Yarasheski², Tim West², Matthew Meyer², Kris Kirmess², Anne Fagan¹, John Morris¹,

Randall Bateman¹

¹*Washington University - St. Louis, MO (USA)*, ²*C2n Diagnostics - St. Louis, MO (USA)*

4.00 p.m

Coffee break and poster session 



● Wednesday,
NOVEMBER 10

4.30 p.m

SYMPOSIUM 3

Bringing Repurposed Drugs to Market: Challenges and Opportunities from Research to Commercialization

Chair: Howard Fillit, Alzheimer's Drug Discovery Foundation - New York, NY (USA)

Repurposing Riluzole for Mild Alzheimer's Disease

Ana Pereira, Icahn School of Medicine At Mount Sinai - New York, NY (USA)

Towards a Phase III Trial of Rotigotine in Combination with Cholinesterase Inhibitors in Patients with Alzheimer's Disease

Giacomo Koch, Fondazione Santa Lucia - Rome (Italy)

Low-dose Levetiracetam for Treatment of Age-related Cognitive Impairment and to Delay Progression of Alzheimer's Dementia

Michela Gallagher, Agenebio - Baltimore, MD (USA)

5.10 p.m

Networking time and receptions

● Thursday,
NOVEMBER 11

All times are USA
Eastern Standard Time



ONSITE PROGRAM LIVE STREAMED TO THE DIGITAL PLATFORM



- 8.00 a.m **KEYNOTE 3**
Vascular Risk Factors and AD: Implications for Therapeutic Trials
Cynthia M. Carlsson, MD, University of Wisconsin School of Medicine and Public Health, Madison, WI (USA)
- 8.20 a.m **ORAL COMMUNICATIONS**
- 8.20 a.m **OC13 - Targeted medication therapy management can successfully augment cognitive reserve in predementia Alzheimer's disease: Results from the INtervention for Cognitive Reserve Enhancement in delaying the onset of Alzheimer's Symptomatic Expression (INCREASE) Study**
Gregory Jicha¹, Erin Abner¹, Frederick Schmitt¹, Lynne Eckmann¹, Mark Huffmyer¹, Ashley Martinez^{1,2}, Brooke Beech^{1,3}, Rosmy George¹, Riham El Khouli¹, Doaa Ali¹, Daniela Moga¹
¹University Of Kentucky - Lexington (USA), ²Harvard Medical School - Boston (USA), ³Washington State University - Pullman (USA)
- 8.35 a.m **OC14 - A model combining tau PET, baseline cognition and neurofilament light optimally predicts**
Ruben Smith¹, Nicholas Cullen¹, Antoine Leuzy¹, Shorena Janelidze¹, Sebastian Palmqvist¹, Niklas Mattsson-Carlgren¹, Oskar Hansson¹
Lund University - Lund (Sweden)
- 8.50 a.m **LATE BREAKING ORAL COMMUNICATIONS: FOCUS ON BIOMARKERS IN AD**
- 8.50 a.m **LB1 - Plasma pTau231 as an early marker of amyloid-β pathology for preclinical Alzheimer's disease trial selection**
Nicholas Ashton¹, Marta Milà-Alomà², Andrea Benedet¹, Thomas Karikari¹, José Luis Molinuevo², Eugeen Vanmechelen³, Henrik Zetterberg¹, Marc Suárez-Calvet², Kaj Blennow¹
¹Gothenburg University - Göteborg (Sweden), ²Barcelona Beta - Barcelona (Spain), ³Adx Neuroscience - Ghent (Belgium)
- 9.05 a.m **LB2 - Association of emerging beta-amyloid and tau pathology with early cognitive changes in clinically normal older adults**
Michelle Farrell¹, Kathryn Papp², Rachel Buckley², Heidi Jacobs¹, Aaron Schultz¹, Michael Properzi¹, Patrizia Vannini², Bernard Hanseeuw¹, Dorene Rentz², Keith Johnson², Reisa Sperling²
¹Massachusetts General Hospital - Boston (United States), ²Massachusetts General Hospital, Brigham & Women's Hospital - Boston (United States)
- 9.20 a.m **LB3 - AlzoSure® Predict, a simple, non-invasive blood test to predict the early onset of Alzheimer's disease with the ability to identify MCI patients, before the clinical symptoms are identifiable (in the same test) 6 years in advance of clinical diagnosis**
Simona Piccirella¹, Leander Van Neste², Christopher Fowler³, James Doecke⁴, Daniela Uberti⁵, Paul Kinnon¹
¹Diadem Srl - Brescia (Italy), ²Halixio Bv - Altenaken (Belgium), ³The Florey Institute Of Neuroscience And Mental Health - Parkville (Australia), ⁴The Australian E-Health Research Centre - Herston (Australia), ⁵Department Of Molecular And Translational Medicine, University Of Brescia - Brescia (Italy)
- 9.35 a.m **LB4 - Introduction of plasma biomarker screening for the AHEAD 3-45 Study**
Reisa Sperling¹, Keith Johnson², Jin Zhou³, Michael C. Irizarry³, Shobha Dhadda³, Lynn D. Kramer³, Chad J. Swanson³, Yarasheski Kevin⁴, Robert A. Rissman⁵, Michael Rafii⁶, Rema Raman⁶, Michael C. Donohue⁶, Gopalan Sethuraman⁶, Paul S. Aisen⁶
¹Brigham And Women's Hospital, Massachusetts General Hospital, Harvard Medical School - Boston (United States), ²Brigham And Women's Hospital, Massachusetts General Hospital, Harvard Medical School - Boston (United States), ³Eisai - San Francisco (United States), ⁴C 2 N Diagnostics - St. Louis (United States), ⁵University Of California San Diego, University Of Southern California - San Diego (United States), ⁶University Of Southern California - San Diego (United States)
- 9.50 a.m Coffee break and poster session 

● Thursday,
NOVEMBER 11

All times are USA
Eastern Standard Time



10.20 a.m **LATE BREAKING ORAL COMMUNICATIONS**

10.20 a.m **LB5 - Efforts to improve recruitment and engagement of underrepresented populations in the Alzheimer's Disease Neuroimaging Initiative (ADNI) Study**

Miriam T. Ashford¹, Ozioma Okonkwo², Monica Rivera Mindt³, Rema Raman⁴, Garrett Miller⁴, Michael C. Donohue⁴, Godfrey A. Coker⁴, Rachel L. Nosheny⁵, Ronald C. Petersen⁶, Paul S. Aisen⁴, Michael Weiner⁷

¹Northern California Institute For Research And Education (ncire), Department Of Veterans Affairs Medical Center - San Francisco (United States),

²Wisconsin Alzheimer's Disease Research Center And The Department Of Medicine, University Of Wisconsin School Of Medicine And Public Health - Madison (United States), ³Psychology & Latin American Latino Studies Institute, Fordham University, Joint Appointment In Neurology, Icahn School Of Medicine At Mount Sinai - New York (United States), ⁴Alzheimer's Therapeutic Research Institute, University Of Southern California - San Diego (United States), ⁵Department Of Psychiatry, University Of California San Francisco - San Francisco (United States), ⁶Department Of Neurology, Mayo Clinic - Rochester (United States), ⁷Department Of Radiology And Biomedical Imaging, University Of California San Francisco - San Francisco (United States)

10.35 a.m **LB6 - LM11A-31 small molecule p75 receptor modulator – phase 2a randomized placebo-controlled safety and exploratory endpoint trial in mild-moderate Alzheimer's disease**

Frank Longo¹, Taylor Schmitz², Hayley Shanks², Eric Reiman³, Kewei Chen³, Stephen Massa⁴, Manfred Windisch⁵

¹Pharmatrophix - Menlo Park (United States), ²Western University - London (Canada), ³Banner Alzheimer's Institute -Phoenix (United States), ⁴Ucsf And Sf Vamc - San Francisco (United States), ⁵Neuroscios - Graz (Austria)

10.50 a.m **LB7 - The cost-effectiveness of aducanumab and donanemab for early Alzheimer's disease in the United States**

Eric Ross^{1,2,3}, Marc Weinberg^{1,2,3}, Steven Arnold^{4,5}, Deborah Blacker^{1,6}

¹Department Of Psychiatry, Massachusetts General Hospital - Boston (United States), ²Department of Psychiatry, McLean Hospital - Belmont (United States), ³Department of Psychiatry, Harvard Medical School - Boston (United States), ⁴Department Of Neurology, Massachusetts General Hospital - Boston (United States), ⁵Department of Neurology, Harvard Medical School - Boston (United States), ⁶Department of Epidemiology, Harvard T.H. Chan School of Public Health - Boston (United States)

11.05 a.m **LB8 - Ketones improve functional connectivity and apparent fiber density in the dorsal attention network: direct links to improved attention and brain energetics in mild cognitive impairment**

Maggie Roy¹, Manon Edde¹, Mélanie Fortier¹, Valérie St. Pierre¹, Christian Bocti¹, Tamas Fulop¹, Maxime Descoteaux¹, Stephen Cunnane¹

Université De Sherbrooke - Sherbrooke (Canada)

11.20 a.m **LB9 - Consistency of Efficacy Assessments Across Various Statistical Methods from the Lecanemab Phase 2 Proof-of-Concept Study, BAN2401-G000-201, in Subjects With Early Alzheimer's Disease**

Shobha Dhadda¹, Michio Kanekiyo¹, David Li¹, Chad Swanson¹, Michael Irizarry¹, Donald Berry², Scott Berry², Lynn Kramer¹

¹Eisai Inc. - Woodcliff Lake (United States), ²Berry Consultants, Llc. - Austin (United States)

11.35 a.m **LATE-BREAKING READOUT ROUNDTABLE 6**

Top-line Results from the GAIN Trial: A Phase 2/3 Study of Atuzaginstat in Mild to Moderate Alzheimer's Disease

Michael Detke¹, Marwan Sabbagh², Mark Ryder³, Joanna Bolger¹, Dave Hennings¹, Shirin Kapur¹, Debasish Raha¹, Florian Ermini¹, Mai Nguyen¹, Ursula Haditsch¹, Kim Perry⁴, Kelly Ritch⁵, Suzanne Hendrix⁶, Sam Dickson⁶, Hatice Hasturk⁷, Sarah Horine¹, Craig Mallinckrodt¹, Leslie Holsinger¹, Casey Lynch¹, Stephen Dominy¹

¹Cortexyme - South San Francisco, CA (USA), ²Cleveland Clinic - Las Vegas, NV (USA), ³UCSF - San Francisco, CA (USA), ⁴Innovative Analytics - Portage, MI (USA), ⁵Datafy Clinical R&D - Portage, MI (USA), ⁶Pentara Corporation - Millcreek, UT(USA), ⁷Forsyth Institute - Cambridge, MA (USA)

12.05 p.m

Lunch

● Thursday,
NOVEMBER 11

All times are USA
Eastern Standard Time



1.20 p.m ORAL COMMUNICATIONS

1.20 p.m **OC15 - Flortaucipir in the Trailblazer-ALZ trial**

Sergey Shcherbinin¹, Ming Lu², Amanda Morris², Ixavier Higgins¹, Cynthia Evans¹, Albert Lo¹, Emily Collins^{1,2}, John Sims¹, Dawn Brooks¹, Mark Mintun^{1,2}

¹Eli Lilly And Company - Indianapolis (USA), ²Avid Radiopharmaceuticals - Philadelphia (USA)

1.35 p.m **OC16 - Effect of racial differences in Alzheimer disease biomarkers on design and analysis of prevention trials**

Chengjie Xiong¹, Tammie Benzinger¹, Suzanne Schindler¹, Anne Fagan¹, Jason Hassenstab¹, John Morris¹

Washington University (USA)

1.50 p.m **OC17 - Why Your Alzheimer's Disease Study Is Going to Fail**

Samuel Dickson¹, Newman Knowlton¹, Jessie Nicodemus Johnson¹, Sean Hennessey¹, Suzanne Hendrix¹

Pentara Corporation - Salt Lake City (USA)

2.05 p.m **OC18 - HOPE4MCI Trial: First Trial Targeting Reduction of Hippocampal Overactivity to Treat Mild Cognitive Impairment due to Alzheimer's Disease with AGB101**

Sharon Rosenzweig-Lipson¹, Russ Barton¹, Michela Gallagher^{1,2}, Richard Mohs¹

¹Agenebio - Baltimore (USA), ²Johns Hopkins University - Baltimore, MD (USA)

2.20 p.m **KEYNOTE 4**

Biostatistics in Alzheimer's Disease Therapeutic Trials: A Future of Convergence

Rema Raman, PhD - Keck School of Medicine, University of Southern California and Director of Biostatistics at USC Alzheimer Therapeutic Research Institute, San Diego, CA (USA)

2.40 p.m ORAL COMMUNICATIONS

2.40 p.m **OC19 - SEMA4D blocking antibody, pepinemab, is a novel potential treatment for neurodegenerative disease: clinical proof of concept in HD supports clinical development in AD**

Terrence Fisher¹, Elizabeth Evans¹, Alisha Reader¹, Vikas Mishra¹, Crystal Mallow¹, Ernest Smith¹, John Leonard¹, Andrew Feigin², Eric Siemers³, Janet Wittes⁴, Maurice Zauderer¹

¹Vaccinex - Rochester (USA), ²For The Huntington Study Group And Signal Investigators And Coordinators - Rochester (USA), ³Siemers Integration Llc - Indianapolis (USA), ⁴For Statistics Collaborative - Washington (USA)

2.55 p.m **OC20 - Current Status and Quantitative Results of the AMYPAD Prognostic and Natural History Study**

Juan Domingo Gispert¹, Lyduine Collij², Katherine Gray³, David Vallez-García², Fiona Heeman², Gemma Salvadó¹, Bruno Dubois⁴, Bruno Vellas⁵, Miia Kivipelto⁶, Agneta Nordberg⁶, Bernard Hansseuw⁷, Mercé Boada⁸, Pablo Martınez-Lage⁹, Andrew Stephens¹⁰, Giovanni Frisoni¹¹, Craig Ritchie¹², Lisa Ford¹³, Pieter Jelle Visser², Gill Farrar¹⁴, Frederik Barkhof²

¹Barcelonabeta Brain Research Center - Barcelona (Spain), ²Amsterdam Umc - Amsterdam (Netherlands), ³Ixico - London (United Kingdom), ⁴Aph - Paris (France), ⁵Chu Toulouse - Toulouse (France), ⁶Karolinska Institutet - Solna (Sweden), ⁷Uc Louvain - Ottignies-Louvain-la-Neuve (Belgium), ⁸Fundació Ace - Barcelona (Spain), ⁹Cita - San Sebastián (Spain), ¹⁰Life Mi - Berlin (Germany), ¹¹University Of Geneva - Geneva (Switzerland), ¹²University Of Edinburgh - Edinburgh (United Kingdom), ¹³Janssen - Raritan (United States), ¹⁴GE Healthcare - Amersham (United Kingdom)

3.10 p.m **OC21 - Dyadic enrollment in a phase 3 mild cognitive impairment clinical trial**

Navneet Hakhu¹, Daniel Gillen¹, Josh Grill¹

University Of California, Irvine - Irvine (United States)

3.25 p.m **OC22 - PIONEER, a Phase 2 Study to Evaluate Treatment with T3D-959 in Patients with Mild to Moderate Alzheimer's Disease: Study Design and Update**

John Didsbury¹, Warren Strittmatter¹, Jessica Stanek¹, Stanley Chamberlain¹, Blake Swearingen¹, Hoda Gabriel¹

T3d Therapeutics, Inc. - Research Triangle Park (United States)

3.40 p.m Coffee break and poster session 

● Thursday,
NOVEMBER 11

All times are USA
Eastern Standard Time



4.10 p.m

ROUNDTABLE 7

Value-Generating Exploratory Trials in Neurodegenerative Dementias

Moderator: Howard Fillit, MD, *Alzheimer's Drug Discovery Foundation, New York, NY (USA)*

Discussants: Jeffrey Cummings, MD, *Chambers-Gundy Center for Transformative Neuroscience, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas (UNLV), NV (USA)*, Michael Gold, MD, *Vice President, Development Neurosciences, AbbVie, Deerfield, IL (USA)*, Suzanne Hendrix, PhD, *President and CEO, Pentara Corporation, Salt Lake City, UT (USA)*

4.40 p.m

ORAL COMMUNICATIONS

4.40 p.m

OC23 – Comparison of the FCSRT and RBANS in screening for early AD clinical trials: Enrichment for disease progression

Edmond Teng¹, Paul Manser¹, Nan Hu¹, Monarch Shah¹, Karen Pickthorn¹, Mira Blendstrup¹, Giuliana Faccin¹, Susanne Ostrowitzki², Kaycee Sink¹

¹Genentech, Inc. - South San Francisco (USA), ²F. Hoffmann-La Roche Ltd. - Basel (Switzerland)

4.55 p.m

OC24 – Effect of Plasma Exchange with Albumin Replacement in Alzheimer's Treatment on Ability to Perform Activities of Daily Living (ADL)

Richard B Lipton¹, Walter F Stewart², Lauren Podger³, David Gomez-Ulloa⁴, M Chris Runken⁵, Miquel Barcelo⁴, Carlota Grifols⁴, Daniel Serrano⁶

¹Albert Einstein College Of Medicine - New York, NY (USA), ²Mercurio Inc - Oakland, CA (USA), ³Open Health Group - Marlow (United Kingdom), ⁴Grifols - Sant Cugat Del Vallès (Spain), ⁵Grifols Ssna - Research Triangle Park, NC (USA), ⁶Open Health Group - Bethesda, MD (USA)

5.10 p.m

Networking time and receptions

● Friday,
NOVEMBER 12

All times are USA
Eastern Standard Time



ONSITE PROGRAM LIVE STREAMED TO THE DIGITAL PLATFORM

- 8.00 a.m. **SYMPOSIUM 4**
Metabolomics a Biochemical Roadmap for Drug Discovery in Alzheimer's Disease
Rima Kaddurah Daouk ¹, Priyanka Baloni ², Kamil Borkowski ³
¹Duke University Medical Center - Durham (United States), ²Institute For Systems Biology - Seattle (United States), ³Univ Of California, Davis - Davis (United States)
- 8.40 a.m. **ORAL COMMUNICATIONS**
- 8.40 a.m. **OC25 – Divergent longitudinal patterns between participant and study partner report on the Cognitive Function Index in the Harvard Aging Brain Study**
Rebecca Amariglio ¹, Rachel Buckley ², Hannah Klinger ², Kathryn Papp ¹, Gad Marshall ¹, Catherine Munro ¹, Jennifer Gatchel ², Patrizia Vannini ¹, Dorene Rentz ¹, Keith Johnson ¹, Reisa Sperling ¹
¹Brigham And Women's Hospital – Boston, MA (USA), ²Massachusetts General Hospital – Boston, MA (USA)
- 8.55 a.m. **OC26 – Functional Connectivity Based Individualized Brain Regions to Measure Tau Propagation: towards application in clinical trials**
Diana Svaldi ¹, Ixavier Higgins ¹, Shcherbinin Sergey ¹, Nicolai Franzmeier ², Michael Ewers ², Emily Collins ¹
¹Eli Lilly And Company - Indianapolis (USA), ²University Hospital Munich - Munich (Germany)
- 9.10 a.m. **OC27 – Practice Effects in the Letter Fluency Test**
Taneisha Arora ¹, Daniel Gillen ², Joshua Grill ², Michelle Nuño ³
¹Google - Mountain View, CA (USA), ²University Of California, Irvine – Irvine, CA (USA), ³University Of Southern California - Los Angeles (USA)
- 9.25 a.m. **LATE BREAKING ORAL COMMUNICATIONS**
- 9.25 a.m. **LB10 – A Digital Remote Memory Composite to Detect Cognitive Impairment in Memory Clinic Samples in Unsupervised Settings using Mobile Devices**
David Berron ¹, Ornella Billette ², Xenia Grande ³, Jeremie Guesten ³, Ina Hempen ⁴, Annika Spottke ⁵, Katharina Buerger ⁶, Robert Pernezcky ⁶, Christoph Laske ⁷, Anja Schneider ⁵, Stefan Teipel ⁸, Jens Wiltfang ⁹, Michael Wagner ⁵, Frank Jessen ¹⁰, Emrah Duzel ¹
¹Dzne, Magdeburg - Magdeburg (Germany), ²Neotiv, Magdeburg - Magdeburg (Germany), ³Univ. Magdeburg - Magdeburg (Germany), ⁴Neotiv. Magdeburg - Magdeburg (Germany), ⁵Dzne, Bonn - Bonn (Germany), ⁶Dzne, Munich - Munich (Germany), ⁷Dzne, Tübingen - Tübingen (Germany), ⁸Dzne, Rostock - Rostock (Germany), ⁹Dzne, Göttingen - Göttingen (Germany), ¹⁰Dzne, Cologne - Cologne (Germany)
- 9.40 a.m. **LB11 – Randomized controlled trial of gamma sensory stimulation treatment demonstrates maintained cognitive and functional abilities and reduced brain atrophy in patients with Alzheimer's disease**
Mihaly Hajos ^{1,2}, Thomas Megerian ^{1,3}, Aylin Cimenser ¹, Alyssa Boasso ¹, Nathan Strozewski ¹, Alex Konisky ¹, Holly Mrozak ¹, Katharine Kolin ¹, Martin Williams ¹, Evan Hempel ¹, Jessie Nicodemus-Johnson ⁴, Suzanne Hendrix ⁴, Brent Vaughan ¹, Zach Malchano ¹
¹Cognito Therapeutics - Cambridge (United States), ²Yale University School of Medicine - New Haven (United States), ³Thompson Autism Center, CHOC Children's - Orange (United States), ⁴Pentara Corporation - Millcreek (United States)
- 9.55 a.m. **LB12 – The Early Mild Alzheimer's Cognitive Composite (EMACC): a meaningful primary cognitive endpoint in a phase 2 trial of XPro1595 in Alzheimer's Disease (AD) with inflammation (ADi)**
Judith Jaeger ¹, Melanie Buitendyk ², Christopher J. Barnum ³
¹Cognitionmetrics And Albert Einstein Col Of Medicine - Stamford Ct And Bronx Ny (United States), ²Cato-Sms - Wilmington, Nc (United States), ³Inmunbio - Boca Raton, Fl (United States)

● Friday,
NOVEMBER 12

All times are USA
Eastern Standard Time



10.10 a.m

LB13 - An Examination of Composite Endpoints in 5 Completed or Terminated AD Prevention Trials

Howard Mackey¹, Angelika Caputo², Michael Donohue³, Nan Hu¹, Jennifer Bogert⁴, Jingtao Wu⁵, Guoqiao Wang⁶
¹Genentech - South San Francisco (United States), ²Novartis Pharma Ag - Basel (Switzerland), ³Alzheimer's Therapeutic Research Institute University Of Southern California - San Diego (United States), ⁴Janssen Research & Development, Llc - Raritan (United States), ⁵Takeda - Cambridge (United States), ⁶Division Of Biostatistics, Washington University - St. Louis (United States)

10.25 a.m

Coffee break and poster session 

10.55 a.m

ORAL COMMUNICATIONS

10.55 a.m

OC28 - Concordance Between the Clinical Dementia Rating (CDR) and the Electronic CDR

Yan Li¹, Taylor Howell², Krista Moulder¹, John Morris¹, Michael Weiner², Rachel Nosheny²
¹Washington University In St. Louis - St. Louis (USA), ²University Of California, San Francisco - San Francisco (USA)

11.10 a.m

OC29 - Quantification of cognitive impairments in preclinical and early Alzheimer's disease: A proof of concept study to investigate the feasibility, adherence and preliminary clinical validity of remote smartphone-based self-assessments of cognition, function and behavior

Thanneer Malai Perumal¹, Arnaud Wolfer¹, Florian Lipsmeier¹, Michael Lindemann¹, Foteini Orfaniotou¹, Simone Rey-Riek¹, Irma T Kurniawan¹, Kirsten Taylor¹
F. Hoffman La Roche Ltd - Basel (Switzerland)

11.25 a.m

OC30 - Integrated Alzheimer's Disease Rating Scale (iADRS): Clinically Meaningful Change Estimates

Dorene Rentz¹, Alette Wessels², Michael Case², John Sims²
¹Harvard Medical School - Boston, MA (USA), ²Eli Lilly and Company - Indianapolis, IN (USA)

11.40 a.m

OC31 - A Multinational, Multi-center, Randomized, Double-blind, Active Comparator, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Donepezil Transdermal Patch in Patients with Alzheimer's Disease

Kee-Hyung Park¹, Won Yang Dong², Mee Young Park³, Seong Hye Choi⁴, Hyun Jeong Han⁴, Hee Jin Kim⁵, Kyung Won Park⁶, Yuan-Han Yang⁷, Suraya Yusoff⁸, Gurudev M. Kewalram⁹, Seol-Heui Han¹⁰
¹Gachon University Gil Medical Center - Incheon (Korea, Republic of), ²The Catholic University Of Korea, Seoul St. Mary's Hospital - Seoul (Korea, Republic of), ³Yeungnam University Hospital - Daegu (Korea, Republic of), ⁴Inha University Medical Center - Incheon (Korea, Republic of), ⁵Hanyang University Seoul Hospital - Seoul (Korea, Republic of), ⁶Dong-A University Hospital - Busan (Korea, Republic of), ⁷Kaohsiung Municipal Ta-Tung Hospital - Kaohsiung (Taiwan, Republic of China), ⁸Hospital Sultan Ismail - Johor Bahru (Malaysia), ⁹Prince Charles Hospital - Brisbane (Australia), ¹⁰Konkuk University Medical Center - Seoul (Korea, Republic of)

11.55 a.m

Lunch break 

1.00 p.m

SYMPOSIUM 5

Diversity in Alzheimer's Disease Clinical Trials

Chair: Holly Massett, National Institute on Aging, U.S. National Institutes of Health, Bethesda, MD, USA

Presentation 1: BRAIN INFO LIVESM: A Free Virtual Outreach Series Reaching Underrepresented US Populations, Bright Focus Foundation

Nancy Lynn, BrightFocus Foundation, Los Angeles, California, USA

Presentation 2: Harnessing Community Data to Drive Brain Health Equity – the National Alzheimer's Disease Index

Jason Resendez, Executive Director, UsAgainstAlzheimer's Center for Brain Health Equity; Washington, DC

Presentation 3: Building an inclusive science that addresses inclusive diverse trials – the NEWIDEAS Study, Alzheimer's Association Consortia

Peggy Dilworth-Anderson, PhD, Gillings School of Global Public Health UNC; Chapel Hill, NC, USA

● Friday,
NOVEMBER 12

All times are USA
Eastern Standard Time



1.40 p.m ORAL COMMUNICATIONS

1.40 p.m **OC32 - Update on the Phase 2 Study of ALO01 in Frontotemporal Dementia Patients Carrying a Granulin Mutation**
Robert Paul¹, Felix Yeh¹, Mike Ward¹, Sam Jackson¹, Herve Rhinn¹, Julie Huang¹, Jenna Pappalardo¹, Yijie Liao¹, Hua Long¹
Alector, Inc. - South San Francisco (USA)

1.55 p.m **OC33 - Centiloid scales may represent a robust clinical outcome for anti-Aβ therapeutic trials across diverse populations/locations**
Samantha C Burnham¹, Timothy Cox², Pierrick Bourgeat³, Vincent Doré¹, Duygu Tosun⁴, Manu Goyal⁵, Rosita Shishegar¹, Parnesh Raniga³, Simon Laws⁶, Tenielle Porter⁶, Jurgen Fripp³, Tammie Benzinger⁷, Walter Kukull⁸, Christopher C Rowe⁹, John C Morris⁷, Mike Weiner⁴, Colin L Masters¹⁰, Victor L Villemagne¹¹
¹The Australian E-Health Research Centre, Csiro Health & Biosecurity - Parkville (Australia), ²The Australian E-Health Research Centre, Csiro Health & Biosecurity - Canberra (Australia), ³The Australian E-Health Research Centre, Csiro Health & Biosecurity - Herston (Australia), ⁴Department Of Radiology And Biomedical Imaging, University Of California-San Francisco - San Francisco (USA), ⁵Neuroimaging Laboratories, Mallinckrodt Institute Of Radiology, Washington University School Of Medicine - St. Louis (USA), ⁶Centre For Precision Health, School Of Medical And Health Sciences, Edith Cowan University - Joondalup (Australia), ⁷Knight Alzheimer Disease Research Center, Washington University School Of Medicine - St. Louis (USA), ⁸Department Of Epidemiology, University Of Washington - Seattle (USA), ⁹Department Of Molecular Imaging & Therapy, Austin Health - Heidelberg (Australia), ¹⁰Florey Institute Of Neuroscience And Mental Health, The University Of Melbourne - Parkville (Australia), ¹¹Department Of Psychiatry, University Of Pittsburgh School Of Medicine - Pittsburgh (USA)

2.10 p.m **OC34 - A machine learning tool to enrich Alzheimer's disease clinical trials in presymptomatic cohorts**
Angela Tam¹, César Laurent¹, Christian Dansereau¹
Perceiv Research Inc - Montreal (Canada)

2.25 p.m **OC35 - The Internet-based conversational engagement clinical trial (I-CONNECT) in socially isolated adults 75+ years old: Randomized controlled trial protocol and COVID-19 related study modifications**
Kexin Yu¹, Lisa C. Silbert², Katherine Wild², Jeffrey A. Kaye², Elena L. Alfaro³, Jacob Lindsey^{4,2}, Colon Scavone², Mattie Mcdonald^{2,5}, Hiroko H. Dodge²
¹University Of Southern California - Los Angeles (USA), ²Oregon Health & Science University - Portland (USA), ³University Of Wisconsin-Madison - Madison (USA), ⁴Oregon State University - Corvallis, OR (USA), ⁵Syneos Health - Portland, OR (USA)

2.40 p.m **OC36 - Development of a novel digital speech composite measure for Frontotemporal Dementia**
Jessica Robin¹, Mengdan Xu¹, Liam Kaufman¹, William Simpson¹, Michael Ward², Robert Paul²
¹Winterlight Labs - Toronto (Canada), ²Alector, Inc. - South San Francisco (USA)

2.55 p.m **OC37 - Longitudinal safety, clinical, and beta amyloid PET outcomes of a multi-center clinical trial of focused ultrasound blood brain barrier (BBB) opening of the hippocampus, frontal and parietal lobes in early Alzheimer's disease**
Ali Rezai¹, Manish Ranjan¹, Mark Haut¹, Jeffrey Carpenter¹, Umer Najib¹, Rashi Mehta¹, Pierre-Francois D'haese¹, J. Levi Chazen², Zion Zibly³, Daniel Claassen⁴, Peter Konrad¹, Sally Hodder⁵, Michael Kaplitt²
¹WVU Rockefeller Neuroscience Institute - Morgantown (USA), ²Weill Cornell Medicine - New York (USA), ³Sheba Medical Center - Ramat Gan (Israel), ⁴Vanderbilt University - Nashville (USA), ⁵West Virginia Clinical and Translational Institute - Morgantown (USA)

3.10 p.m **Statistics workshop: re-thinking trial outcomes**
Paul Aisen, MD, *ATRI at USC, San Diego, CA (USA)*, Hong Liu Seifert, *Eli Lilly & Company, Indianapolis, IN (USA)*

ONSITE POSTER PRESENTATIONS



- **THEME**
Animal model and clinical trial
 - **THEME**
Behavioral disorders and clinical trials
 - **THEME**
Clinical trials: cognitive and functional endpoints
 - **THEME**
Clinical trials: imaging
 - **THEME**
Clinical trials: biomarkers including plasma
 - **THEME**
Clinical trials: methodology
 - **THEME**
Clinical trials: results
 - **THEME**
Cognitive assessment and clinical trials
 - **THEME**
Epidemiology and clinical trials
 - **THEME**
Digital health/E-trials
 - **THEME**
Health economics and clinical trials
 - **THEME**
New therapies and clinical trials
 - **THEME**
Proof of concept/Translational research for Alzheimer Drug Development interventions
- P1
- P2 to P4
- P7 to LP2
- P12 to LP5
- P20 to LP9
- P27 to LP12
- P42 to LP18
- P48 to LP21
- P61 to LP23
- P64 to LP26
- P68 to LP27
- P70 to LP31
- P73 to LP32

Poster presented onsite in Boston

These posters will be available in the poster hall at the Conference Venue, with specific "meet the presenters" sessions during coffee breaks and lunches.

Furthermore, all posters presented onsite in Boston will also be available at all times on the digital platform to be viewed by participants attending remotely or in-person.



POSTERS presented onsite in Boston

THEME

Animal model and clinical trial

- P1** Treatment of Alzheimer's disease by a proteasome-based adjuvant (Protollin) that modulates both peripheral monocytes and disease-associated microglia
Panayota Kolypetri
Brigham Women's Hospital – Boston, MA (USA)

THEME

Behavioral disorders and clinical trials

- P2** Mapping Items of the Cohen-Mansfield Agitation Inventory onto International Psychogeriatric Association's agitation definition: data from the brexpiprazole phase 3 program for the treatment of agitation in Alzheimer's dementia
Ross A. Baker¹, Eva Kohegyi¹, Ismail Zahinoor²
¹Otsuka – Princeton, NJ (USA), ²University of Calgary - Calgary (Canada)
- P3** Veterans in AD Prevention Clinical Trials: An evaluation of the association of TBI on memory and global cognition
Carol Van Hulle¹, Madison Rundell¹, Karen Lazar¹, Elena Beckman¹, Noele Brandon¹, Carey Gleason¹, Sterling Johnson¹, Sanjay Asthana¹, Cynthia Carlsson¹
University of Wisconsin-Madison – Madison, WI (USA)
- P4** Low dose lithium treatment of behavioral complications in Alzheimer's disease: Lit-AD randomized clinical trial
Davangere Devanand¹, Elizabeth Crocco¹, Brent Forester¹, Mustafa Husain¹, Seonjoo Lee¹
Columbia University Irving Medical Center - New York (USA)

THEME

Clinical trials: cognitive and functional endpoints

- P7** iADRS: demonstration of clinical meaningfulness by association of health-related quality of life outcome assessments
Julie Chandler¹, Mark Belger¹, Alette Wessels¹, Joe Johnston¹, Dorene Rentz^{2,3}, James Murray¹, John Sims¹
¹Eli Lilly And Company - Indianapolis (USA), ²Department Of Neurology, Massachusetts General Hospital, Harvard Medical School - Boston (USA), ³Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School - Boston (USA)
- P8** Repeated administration of autologous adipose tissue-derived stem cells improved cognitive function in Alzheimer's disease
Kazuo Shigematsu^{1,2}, Kazunari Ishii³, Naoyuki Komori², Kenichi Tahara⁴, Hisakazu Yamagishi⁵
¹Minami Kyoto Hospital - Jyojo (Japan), ²Nagitsuji Hospital - Kyoto (Japan), ³Department Of Radiology, Kindai University Faculty Of Medicine - Osakasayama (Japan), ⁴Takara Bio Inc - Kusatsu (Japan), ⁵Kyoto Prefectural University Of Medicine - Kyoto (Japan)
- P9** The Influence of Level of Education on Instrumental Activities of Daily Living in Patients with Alzheimer's Disease
Carina Wattmo
Clinical Memory Research Unit, Department of Clinical Sciences, Malmö, Lund University - Malmö (Sweden)
- P10** Low-dose Whole Brain Radiation Therapy for Early Alzheimer's Dementia: Early Results from a Phase IIa Trial
Leland Rogers¹, Sarah Lageman², John Karis³, Minesh Mehta⁴, James Fontanesi⁵
¹Gammawest Cancer Services - Salt Lake City, Ut (USA), ²Virginia Commonwealth University - Richmond, Va (USA), ³Barrow Neurological Institute - Phoenix, Az (USA), ⁴Miami Cancer Institute - Miami, Fl (USA), ⁵William Beaumont Hospital - Auburn Hills, Mi (USA)
- P11** AMBAR Treatment Effect Size Compared to Monoclonal Antibody Study Effect Sizes
Samuel Dickson¹, Suzanne Hendrix¹, Jessie Nicodemus Johnson¹, Miquel Barcelo², Merce Boada^{3,4}, Oscar Lopez⁵, Laura Nunez², Carlota Grifols², Antonio Paez²
¹Pentara Corporation - Millcreek (USA), ²Grifols - Barcelona (Spain), ³Universitat Internacional De Catalunya - Barcelona (Spain), ⁴Instituto de Salud Car
- LP1** Validation of the Learning Ratio derived from the RAVLT in Early-Onset Alzheimer's Disease from the LEADS study
Dustin Hammers¹, Taylor Diedrich¹, Sara Nemes¹, Ani Eloyan², Joel Kramer³, Paul Aisen⁴, Maria Carillo⁵, Bradford Dickerson⁶, Gil Rabinovici³, Liana Apostolova¹, Leads Leads Consortium¹
¹Indiana University - Indianapolis (United States), ²Brown University - Providence (United States), ³University Of California San Francisco - San Francisco (United States) - San Francisco (United States), ⁴University Of Southern California - Los Angeles (United States), ⁵Alzheimer's Association - Chicago (United States), ⁶Mass General Brigham Harvard - Boston (United States) - Boston (United States)

● POSTERS presented onsite

LP2 Sensitivity of the Preclinical Alzheimer's Cognitive Composite (PACC), PACC5, and Repeatable Battery for Neuropsychological Status (RBANS) to Amyloid Status in Preclinical Alzheimer Disease -Atabecestat Phase 2b/3 EARLY Clinical Trial

Kate Papp¹, Hany Rofael², Amy Veroff³, Mike Donohue⁴, Shunran Wang⁴, Christopher Randolph⁵, Ellen Grober⁶, H. Robert Brashear⁷, Gerald Novak⁸, Karin Ernstrom⁴, Rema Raman⁴, Paul Aisen⁴, Reisa Sperling¹, Gary Romano⁸, David Henley⁹

¹Harvard Medical School - Boston (United States), ²Janssen Research And Development - Titusville (United States), ³Consultant - Bethesda (United States), ⁴University Of Southern California - San Diego (United States), ⁵Medavante - Hamilton (United States), ⁶Albert Einstein College Of Medicine - Bronx (United States), ⁷University Of Virginia - Charlottesville (United States), ⁸Janssen - Titusville (United States), ⁹Indiana University School Of Medicine - Indianapolis (United States)

THEME

Clinical trials: imaging

P12 An automated MRI face-removal pipeline to anonymize patient scans for clinical trials

Lukasz Kidzinski¹, Thomas Cajgfinger², Kevin Thomas¹, Luc Bracoud², Po-Han Chen³, Shao-Yu Lin³, Joonmi Oh¹, Chun-Chiang Shen³, Chris Conklin⁴, Joël Schaerer², David Scott¹, Joyce Suhy¹

¹Bioclinica - San Mateo (USA), ²Bioclinica - Lyon (France), ³Bioclinica - Taiwan (Taiwan, Republic of China), ⁴Bioclinica - Princeton (USA)

P13 Free water imaging as a tool for understanding Alzheimer's Disease

Richard Parker¹, Richard Joules¹, Robin Wolz¹

Ixico Plc - London (United Kingdom)

P14 Impact of Age and APOE4 carrier status in subjects at-risk for AD on microhemorrhages, white matter lesions and brain volume: Preliminary analyses

Luc Bracoud¹, Marie-Emmanuelle Rivièrè², David Scott³, Chris Conklin⁴, Angelika Caputo², Joyce Suhy³, Ana Graf²

¹Bioclinica - Lyon (France), ²Novartis Pharma Ag - Basel (Switzerland), ³Bioclinica - San Mateo (USA), ⁴Bioclinica - Princeton (USA)

P15 Towards computer-assisted detection of ARIA-E occurrence

Thomas Cajgfinger¹, Luc Bracoud¹, Derk Purcell², Joël Schaerer¹, Marco Lyons³, Szofia Bullain³, Jakub Wojtowicz⁴, Chris Conklin⁵, David Scott⁶, Joyce Suhy⁶, Gregory Klein⁴

¹Bioclinica - Lyon (France), ²California Pacific Medical Center - San Francisco (USA), ³Roche/genentech Product Development, Neuroscience - Basel (Switzerland), ⁴Roche Pharma Research and Early Development - Basel (Switzerland), ⁵Bioclinica - Princeton (USA), ⁶Bioclinica - San Mateo (USA)

P16 Allopregnanolone as a Regenerative Therapeutic for Alzheimer's Disease: Phase 2 proof-of-concept clinical trial using hippocampal volume as a surrogate endpoint

Gerson Hernandez¹, Lon Schneider², Dawn Matthews³, Kathleen Rodgers¹, Claudia Lopez¹, Yvette Wang¹, Adam Raikes¹, Gary Cutter⁴, Roberta Brinton¹

¹Center For Innovation In Brain Science, University Of Arizona - Tucson (USA), ²Keck School Of Medicine Of USC - Los Angeles (USA), ³Adm Diagnostics - Chicago (USA), ⁴Uab School Of Public Health - Birmingham (USA)

P17 Safety, Tolerability and Cerebral Blood Flow After Single Doses of the β 2-agonist, Clenbuterol, in Patients with Mild Cognitive Impairment or Parkinson's Disease

Thomas Lodewyckx¹, Jan De Hoon¹, Koen Van Laere², Michel Koole¹, Wim Vandenberghe³, Courtney Bishop⁴, Eugenii Rabiner⁴, Renee Martin⁵, Anthony Ford⁵, Gabriel Vargas⁵

¹Department Of Pharmaceutical And Pharmacological Sciences, Ku Leuven - Leuven (Belgium), ²Division Of Nuclear Medicine, University Hospital Leuven And Nuclear Medicine And Molecular Imaging - Durham (USA), ³Department Of Neurology, University Hospital Leuven - Leuven (Belgium), ⁴Invicro, A Konica Minolta Company - London (United Kingdom), ⁵Curasen Therapeutics, Inc - San Carlos, California (USA)

P19 Regional amyloid accumulation predicts memory decline in initially cognitively unimpaired individuals

Lyduine Collij¹, Sophie Mastenbroek¹, Gemma Salvadó², Alle Meie Wink¹, Pieter Jelle Visser¹, Frederik Barkhof¹, Bart Berckel Van¹, Isadora Lopes Alves¹

¹Amsterdam Umc - Amsterdam (Netherlands), ²Barcelonabeta Brain Research Center - Barcelona (Spain)

LP3 Novel white matter imaging measures of neuroinflammation, axonal density and demyelination as potential biomarkers for trials in the AD spectrum: validation in the largescale longitudinal multicenter ADNI studies

Maggie Roy¹, Matthieu Dumont¹, Jean-Christophe Houde¹, Raymond Tesi², Christopher Barnum², Maxime Descoteaux¹, Alzheimer's Disease Neuroimaging Initiative Alzheimer's Disease Neuroimaging Initiative³

¹Imeka Solutions Inc - Sherbrooke (Canada), ²Inmune Bio, Inc - San Diego (United States), ³Alzheimer's Disease Neuroimaging Initiative - San Diego (United States)

LP4 MRI measures of white matter pathology in AD clinical trials - case study from the XPro1595 phase 1 trial in Alzheimer's patients with neuroinflammation

Maxime Descoteaux^{1,2}, Maggie Roy¹, Matthieu Dumont¹, Jean-Christophe Houde¹, Parris Pope³, R.j Tesi³, C.j Barnam³

¹Imeka Solutions Inc - Sherbrooke (Canada), ²Université de Sherbrooke - Sherbrooke (Canada), ³Inmune Bio Inc - San Diego (United States)

LP5 Anatomical and Functional connectivity of the Nucleus Basalis in Alzheimer's Disease

Sergio Becerra^{1,2}, Sheldon Jordan^{1,2}, Taylor Kuhn^{1,2}, Kennedy Mahdavi¹, Jon Haroon¹, Margaret Zielinski¹

¹Synaptec Network - Santa Monica, Ca (United States), ²UCLA - Los Angeles, Ca (United States)

● POSTERS presented onsite

THEME

Clinical trials: biomarkers including plasma

- P20** Microglia biomarkers in Alzheimer's disease
Peng-Fei Zhang
Qingdao University - Qingdao (China)
- P22** Alzheimer's disease Patients have Impaired CSF Egress due to Atrophy of the Cribriform Plate
Douglas Ethell 1, 2, Ricardo Zaragoza 1, Javed Siddiqi 3, Daniel Miuli 4
1Leucadia Therapeutics Inc - Riverside (USA), 2La Jolla Immunology Institute - San Diego (USA), 3Desert Regional Med Ctr - Palm Springs (USA), 4Arrowhead Regional Med Ctr - Colton (USA)
- P23** Longitudinal plasma phosphorylated tau 181 tracks disease progression in Alzheimer's disease
Shi-Dong Chen 1, Qiang Dong 1, Jin-Tai Yu 1
Department Of Neurology And Institute Of Neurology, Huashan Hospital, Shanghai Medical College, Fudan University - Shanghai (China)
- P24** Can EEG biomarkers differentiate Alzheimer's disease dementia vs. non-AD dementia?
Pieter Van Mierlo 1, 2
1Ghent University - Ghent (Belgium), 2Epilog Nv - Ghent (Belgium)
- P26** Characterization of Alzheimer's tau biomarker discordance using plasma, CSF and PET
Guo Yu
Department Of Neurology And Institute Of Neurology, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China - Shanghai (China)
- LP6** Extracellular vesicle biomarkers of insulin signaling associate with age-related change in CSF biomarkers of Alzheimer's disease in adults without dementia
Gilda Ennis 1, Erden Eren 2, Yue Ma 1, Corinne Engelman 1, Rozalyn Anderson 1, Ivonne Suridjan 3, Gwen Kollmorgen 4, Cynthia Carlsson 1, Sanjay Asthana 1, Sterling Johnson 1, Henrik Zetterberg 5, Kaj Blennow 5, Barbara Bendlin 1, Dimitrios Kapogiannis 2
1University Of Wisconsin-Madison - Madison (United States), 2National Institute On Aging - Baltimore (United States), 3Roche Diagnostics International Ltd - Rotkreuz (Switzerland), 4Roche Diagnostics GmbH - Penzberg (Germany), 5University Of Gothenburg - Gothenburg (Sweden)
- LP8** Cerebrospinal Fluid Biomarkers in Early Alzheimer's Disease Subjects with APOE4/4 and APOE3/4 Genotypes: Baseline Data from Phase 2 Biomarker Study with Oral Anti-Amyloid Agent ALZ-801
John Hey 1, Susan Abushakra 1, Aidan Power 1, Sterre Rutgers 2, Katerina Sheardova 3, Paul Dautzenberg 4, Niels Prins 2, Ladislav Pazdera 5, Earvin Liang 1, Kaj Blennow 6, Philip Scheltens 7, Jakub Hort 8, Martin Tolar 1
1Alzheon Inc. - Framingham (United States), 2Brain Research Center - Amsterdam (Netherlands), 3St. Anne University Hospital - Brno (Czech Republic), 4Brain Research Center - Den Bosch (Netherlands), 5Vestra Research Clinics - Rychnov And Knežnou (Czech Republic), 6Gothenberg University - Molndal (Sweden), 7Amsterdam University Medical Centers, Alzheimers Center - Amsterdam (Netherlands), 8Charles University Cognitive Center, Motol Hospital - Prague (Czech Republic)
- LP9** Brain Hippocampal Volume and Cortical Thickness in Early Alzheimer's Disease Subjects with APOE4/4 and APOE3/4 Genotypes: Baseline Data from Phase 2 Biomarker Study with the Oral Anti-Amyloid Agent ALZ-801
Susan Abushakra 1, John Hey 1, Luc Bracoud 2, Aidan Power 1, Joyce Suh 3, Jakub Hort 4, Sheardova Katerina 5, Pazdera Ladislav 6, Rutgers Sterre 7, Scheltens Philip 8, Tolar Martin 1
1Alzheon Inc. - Framingham (United States), 2Bioclinica - Leon (France), 3Bioclinica - San Mateo (United States), 4Charles University - Prague (Czech Republic), 5St. Anne University Hospital - Brno (Czech Republic), 6Vestra Research Clinics - Rychnov And Knežnou (Czech Republic), 7Brain Research Center - Amsterdam (Netherlands), 8Amsterdam University Alzheimer Center - Amsterdam (Netherlands)

THEME

Clinical trials: methodology

- P27** Placebo-effect size in symptomatic Alzheimer's Disease Clinical Trials
Nadine Mader 1, Peter Schueler 2
1Univ Duisburg Essen - Bad Vilbel (Germany), 2Icon - Langen (Germany)
- P28** Effects of Orally Administered Nicotinamide Riboside on Bioenergetic Metabolism, Oxidative Stress and Cognition in Mild Cognitive Impairment and Mild Alzheimer's Disease
Isabella Santangelo 1, Morgan Green 1, Regan Patrick 1, David Harper 1, Tao Song 1, Chenyanwen Zhu 1, Boyu Ren 1, Brent Forester 1, Fei Du 1
Mclean Hospital - Belmont (USA)

● POSTERS presented onsite

- P30** **Caring for Behavioral Symptoms of Dementia (CBD): A New Investigation into Cannabidiol for the Treatment of Anxiety and Agitation in Alzheimer's Dementia**
Kaitlin Mcmanus 1, Rosemary Smith 1, Regan Patrick 1, David Harper 1, Staci Gruber 1, Brent Forester 1
Mclean Hospital - Boston (USA)
- P31** **ECT-AD Trial: Challenges to Startup & Recruitment**
Maria Lapid 1, Brent Forester 2, George Petrides 3, Adriana Hermida 4, Louis Nykamp 5, Martina Mueller 6, Regan Patrick 2
1Mayo Clinic - Rochester, Mn (USA), 2Mclean Hospital - Belmont, Ma (USA), 3Northwell Health/zucker Hillside Hospital - Glen Oaks, Ny (USA), 4Emory University Healthcare - Atlanta, Ga (USA), 5Pine Rest Christian Mental Health Services - Grand Rapids, Mi (USA), 6Medical University Of South Carolina - Charleston, Sc (USA)
- P32** **The Impact of MMSE Administration Errors on MMSE Change One Year After Randomization: A Preliminary Analysis of Pooled Data**
David Miller 1, Xingmei Wang 1, Alan Kott 2
1Signant Health - Blue Bell, PA (USA), 2Signant Health - Prague (Czech Republic)
- P33** **The ANeED Study: Amboxol in New and Early Dementia with Lewy Bodies**
Arvid Rongve
Haugesund (Norway)
- P34** **Age affects clinical outcome in Alzheimer's disease trials**
Steven Targum 1, Lisa Fosdick 2, Kristin Drake 3, Paul Rosenberg 4, Anna Burke 5, David Wolk 6, Kelly Foote 7, Wael Asaad 8, Marwan Sabbagh 9, Gwenn Smith 4, Andres Lozano 10, Constantine Lyketsos 4
1Functional Neuromodulation Ltd - Boston (USA), 2Functional Neuromodulation Ltd - Phoenix (USA), 3Functional Neuromodulation Ltd - Dallas (USA), 4Johns Hopkins University School Of Medicine - Baltimore (USA), 5Department Of Neurology, Barrow Neurological Institute - Phoenix (USA), 6University Of Pennsylvania - Philadelphia (USA), 7University Of Florida, Fixel Institute For Neurological Diseases - Gainesville (USA), 8Alpert Medical School Of Brown University - Providence (USA), 9Cleveland Clinic Lou Ruvo Center For Brain Health - Las Vegas (USA), 10University Of Toronto - Toronto (Canada)
- P35** **Effects of inclusion/exclusion criteria on ethnocultural and socioeconomic composition of participants in an Alzheimer's disease clinical trial: Analysis of Health and Retirement Study (HRS) data**
Miriam T. Ashford 1, Mohammed U. Kabeto 2, Caroline R. Wixom 3, 4, 5, Rachel L. Nosheny 6, Michael W. Weiner 7, David R. Weir 8, Kenneth M. Langa 8, 9, 10
1Northern California Institute For Research And Education (ncire), Department Of Veterans Affairs Medical Center - San Francisco (USA), 2Department Of Internal Medicine, University Of Michigan - Ann Arbor (USA), 3General Medicine, Department Of Internal Medicine, University Of Michigan - Ann Arbor (USA), 4Department Of Medicine, University Of California San Francisco - San Francisco (USA), 5Department Of Neurology, University Of California San Francisco - San Francisco (USA), 6Department Of Psychiatry, University Of California San Francisco - San Francisco (USA), 7Department Of Radiology And Biomedical Imaging, University Of California San Francisco - San Francisco (USA), 8Institute For Social Research, University Of Michigan - Ann Arbor (USA), 9Department Of Medicine, University Of Michigan - Ann Arbor (USA), 10Institute for Healthcare Policy and Innovation, University Of Michigan - Ann Arbor (USA)
- P36** **A machine learning tool to enrich early Alzheimer's disease clinical trial cohorts**
Angela Tam 1, César Laurent 1, Christian Dansereau 1
Perceiv Research Inc - Montreal (Canada)
- P37** **Enhancing the Enrollment of Underrepresented Minority Populations in Clinical Trials Through the Global Alzheimer's Platform Foundation's® (GAP's) Diversity and Inclusion Program**
Tamiko Rodgers 1, Leigh Zisko 1, John Dwyer 1, Judith Jeter 1, Cyndy Cordell 1
Global Alzheimer's Platform Foundation - Washington, DC (USA)
- P38** **Comprehensive evaluations of some mixed models for clinical trial analysis in Alzheimer disease**
Guoqiao Wang
Washington University In St Louis - St Louis, MI (USA)
- P39** **Predicting Amyloid Positivity Using Machine Learning-Based Risk Scores**
Kellen Petersen 1, Ali Ezzati 1, Richard Lipton 1, Ellen Grober 1
Albert Einstein College of Medicine - Bronx, NY (USA)
- P40** **Determining the Probability of Success in a Clinical Development Program for a Disease Modifying AD Treatment**
Suzanne Hendrix 1, Newman Knowlton 1, Jessie Nicodemus Johnson 1, Sean Hennessey 1, Samuel Dickson 1
Pentara Corporation - Salt Lake City (USA)
- LP10** **Preclinical AD Research and the Electronic Medical Record (EMR): Balancing Confidentiality and Participant Safety**
Seth Gale 1, Judith Heidebrink 2, Jonathan Graff-Radford 3, Joshua Grill 4, Gregory Jicha 5, Jason Karlawish 6, William Menard 7, Milap Nowrangi 8, Susi Sami 9, Shirley Sirivong 4, Sarah Walter 10
1Brigham And Women's Hospital - Boston (United States), 2University Of Michigan - Ann Arbor (United States) - Ann Arbor (United States), 3Mayo Clinic - Rochester (United States), 4University Of California - Irvine (United States), 5University Of Kentucky - Lexington (United States), 6University Of Pennsylvania - Philadelphia (United States), 7Butler Hospital, Memory And Aging Center - Providence (United States), 8Johns Hopkins University - Baltimore (United States), 9Case Western Reserve University - Cleveland (United States), 10Alzheimer's Therapeutic Research Institute, University Of Southern California - San Diego (United States)

● POSTERS presented onsite

LP11 Planning for Success: a Three-step process to Define Phase II Trial Size and Duration Using a Patient Enrichment Strategy using Phase I Data and Public Databases

Cj Barnum 1, 2, Descoteaux Maxime 3, Roy Maggie 4, Dumont Matthieu 4, Jean-Christophe Houde 4, Melanie Buitendyk 5, Judith Jaeger 6, Rj Tesi 1
1Immune Bio Inc - Boca Raton (United States), 2Imeka Solutions Inc - Sherbrooke (Canada), 3Université De Sherbrooke - Sherbrooke (Canada), 4Imeka Solutions Inc - Sherbrooke (Canada), 5Cato-Sms - Wilmington (United States), 6Cognition Metrics Llc - Springfield (United States)

LP12 Preferences for Disclosure of Biomarker and Genetic Results in Alzheimer's Research: Feedback from a Participant Advisory Board

Sarah Walter 1, Adam Boxer 2, Joshua D. Grill 3, Jason Karlawish 4, Shaffer Elizabeth 1, Jaimie Ziolkowski 5, Paul Aisen 1
1 alzheimer's Therapeutic Research Institute, University Of Southern California - San Diego (United States), 2 university Of California, San Francisco - San Francisco (United States), 3 university Of California, Irvine - Irvine (United States), 4 university Of Pennsylvania, Perelman Medical School - Philadelphia (United States), 5 University Of Michigan - Detroit (United States)

THEME

Clinical trials: results

P42 CPAD: Accelerating Alzheimer's disease drug development through pre-competitive data sharing and generation of data-driven quantitative drug development tools

Sudhir Sivakumaran 1, Jackson Burton 1, Yashmin Karten 1, Zihan Cui 1, Bob Stafford 1, Corissa Lau 1, Eileen Priest 1, Hazel White 1, Michael Irizarry 2, Klaus Romero 1
1Critical Path Institute - Tucson (USA), 2Eisai Inc. - Woodcliff Lake (USA)

P43 Interim Results of an Open-label Study of Simufilam in Mild-to-Moderate Alzheimer's Disease

Lindsay Burns 1, Tamara Doehner 2, John Puente 2, Brian Beck 3, Yaneicy Gonzalez Rojas 4, Evelyn Lopez-Brignoni 5, Boris Nikolov 5, Ben Murray 1, Antonio Hernandez 1, Carrie Crowley 1, Nadav Friedmann 1
1Cassava Sciences - Austin (United States), 2Cognitive Clinical Trials - Omaha (United States), 3Cognitive Clinical Trials - Phoenix (United States), 4Optimus U - Miami (United States), 5Imic Research - Palmetto Bay (United States)

P44

P45 A Phase 1 Study of ALOO3 in Healthy Volunteers and Participants with Alzheimer's disease

Mike Ward 1, Felix Yeh 1, Hua Long 1, Tina Schwabe 1, Herve Rhinn 1, Ilaria Tassi 1, Daniel Maslyar 1, Madeline Spencer 1, Candace Hagey 1, Glenn Morrison 1, Robert Paul 1
Alector, Inc. - South San Francisco (USA)

P46 A First-in-human Study of the anti-Sortilin antibody AL101

Mike Ward 1, Daniel Maslyar 1, Felix Yeh 1, Hua Long 1, Michael Kurnellas 1, Emmanuel Ang 1, Amber Silva 1, Robert Paul 1
Alector Inc. - South San Francisco (USA)

LP13 Positive clinical outcomes of posiphen in two phase2a studies-- Alzheimer' disease and Parkinson's disease

Maria Maccecchini 1, Cheng Fang 1, Henrik Zetterberg 2, Michael Chen 3
1Annovis Bio - Berwyn (United States), 2University Of Gothenburg - göteborg (Sweden), 3Tcm - New Jersey (United States)

LP14 Impact of Alzheimer's disease (AD) related co-pathology on treatment effects of the oral p38 α kinase inhibitor neflamapimod in mild-to-moderate dementia with Lewy bodies (DLB)

John Alam 1, Stephen Gomperts 2, 3, Afina Lemstra 4, 5, Inge Verberk 4, Sherif Bayoumi 4, Hui-May Chu 6, Amanda Gardner 1, Kelly Blackburn 1, Niels Prins 4, 5, Charlotte Teunissen 4
1Eip Pharma - Boston (United States), 2Massachusetts Alzheimer's Disease Research Center - Boston (United States) - Boston (United States), 3Massachusetts General Hospital - Boston (United States), 4Amsterdam Umc - Amsterdam (Netherlands), 5Brain Research Center - Amsterdam (Netherlands), 6Anoixis Corporation - Natick (United States)

LP15 Safety and Biological Activity of a Fixed-Dose Coformulation of Sodium Phenylbutyrate and Taurursodiol (PB/TURSO) for the Treatment of Alzheimer's Disease: Results From the Phase 2a PEGASUS Study

Steven E. Arnold 1, Suzanne Hendrix 2, Jessie Nicodemus-Johnson 2, Newman Knowlton 2, Alison J. Mcmanus 1, Monica Crane 3, Sanjeev N. Vaishnavi 4, Jeffrey M. Burns 5, Zoe Arvanitakis 6, Judith Neugroschl 7, Victoria J. Williams 8, Rudolph E. Tanzi 9, Patrick D. Yeramian 10, Kent Leslie 10
1Department Of Neurology, Massachusetts General Hospital, Boston, Ma - Boston (United States), 2Pentara Corporation, Millcreek, Ut - Millcreek (United States), 3Genesis Neuroscience Clinic, Knoxville, Tn - Knoxville (United States), 4Department Of Neurology, Perelman School Of Medicine At The University Of Pennsylvania, Philadelphia, Pa - Philadelphia (United States), 5University Of Kansas Alzheimer's Disease Center, Kansas City, Ks - Kansas City (United States), 6Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Il - Chicago (United States), 7Department Of Psychiatry, Icahn School Of Medicine At Mount Sinai, New York, Ny - New York (United States), 8Department Of Medicine, University Of Wisconsin-Madison, School Of Medicine And Public Health, Madison, Wi - Madison (United States), 9Sean M. Healey And Amg Center For Als & The Neurological Clinical Research Institute, Massachusetts General Hospital, Harvard Medical School, Boston, Ma - Boston (United States), 10Amylyx Pharmaceuticals, Inc., Cambridge, Ma - Cambridge (United States)

● POSTERS presented onsite

LP16 RetiSpec's Hyperspectral Imaging System: Results of a Validation Study in Preclinical AD and MCI
Sharon Cohen 1, Arthur Plante 2, 3, 4, Alon Hazan 5, Adam Gribble 5, Yi Ping Lin 5, Justin Digregorio 5, Westreich Jared 5, Ian Cohen 1, Andriy Strilchuk 1, Julie Soehner 1, Fred Leblond 6, 7, Michal Schnaider-Beeri 8
1Toronto Memory Program - Toronto (Canada), 2Retispec Inc. - Montréal (Canada), 3Department of Engineering Physics, Polytechnique Montreal - Montréal (Canada), 4Centre de recherche du Centre hospitalier de l'Université de Montréal - Montréal (Canada), 5Retispec Inc - Toronto (Canada), 6Department Of Engineering Physics, Polytechnique Montreal, Montreal, Quebec, Canada; Centre De Recherche Du Centre Hospitalier De L'universite De Montréal, - Montréal (Canada), 7Centre De Recherche Du Centre Hospitalier De L'universite De Montréal, - Montréal (Canada), 8The Joseph Sagol Neuroscience Center, Sheba Medical Center, Israel; Professor, Icahn School Of Medicine At Mount Sinai - Tel Hashomer (Israel)

LP17 Mapping the Cohen-Mansfield Agitation Inventory to the Clinical Global of Severity of Agitation: data from the brexpiprazole phase 3 program for the treatment of agitation in Alzheimer's dementia
Anne De Jong-Laird 1, Pedro Such 2, Dalei Chen 3, Ross Baker 3
1Otsuka - The Hague (Netherlands), 2Lundbeck - Copenhagen (Denmark), 3Otsuka - Princeton (United States)

LP18 Final Data From a Phase 1 Single-Ascending-Dose Trial of PNT001, A Monoclonal Antibody Uniquely Recognizing cis-pT231 Tau for Treatment of Tauopathies
Wendy Luca 1, Kelly Foster 1, Kim Mc Clure 1, Martin Jefson 1, Michael Ahljanian 1, Larry Altstiel 1
Pinteon Therapeutics - Newton Centre (United States)

THEME

Cognitive assessment and clinical trials

P48 Cultural Influence on CDR Scores: Comparison across Seven Geo-Cultural Groups
Sayaka Machizawa 1, Todd Feaster 1, Jessica Stenclik 1, Zinan Chen 1, Danielle Digregorio 1
Signant Health - Blue Bell (USA)

P49 Geo-Cultural Influences on MMSE Total Score in Alzheimer's Disease Trials
Jessica Stenclik 1, Sayaka Machizawa 1, Zinan Chen 1, Todd Feaster 1
Signant Health - Blue Bell (USA)

P50 Different methods of identifying rapid cognitive decliners for Alzheimer's Disease
Haiyang Zhang 1, Jason Goode 1, Michael Donahue 2, Ali Torkamani 3, Jared Cara 1, Julie Collens 1
1Vivid Genomics - San Diego (USA), 2University Of Southern California - Los Angeles (USA), 3Scripps Research Institute - San Diego (USA)

P51 Quick Dementia Rating System and its relationship to neuropsychological scores and biomarkers
Kevin Duff 1, Deborah Levine 2, Bruno Giordani 2, Angie Fagerlin 1, Nicole Fowler 3, John Hoffman 1
1University Of Utah - Salt Lake City, UT (USA), 2University Of Michigan - Ann Arbor, MI (USA), 3Indiana University - Bloomington, IN (USA)

P52 Can scores on the Repeatable Battery for the Assessment of Neuropsychological Status predict amyloid deposition?
Kevin Duff 1, Kayla Suhrie 1, Dustin Hammers 2, Ava Dixon 1, John Hoffman 1
1University Of Utah (USA), 2Indiana University (USA)

P53 Detection of Pre-clinical Alzheimer's Disease with Simultaneous Modeling of Underlying Cognitive Processes in Recall and Recognition Tests
Jason Bock 1, Michael Lee 2, William Shankle 1, 2, 3, Junko Hara 1, 3, Dennis Fortier 1, Tushar Mangrola 1
1Embic - Newport Beach (USA), 2Dept. Of Cognitive Sciences, University Of California At Irvine - Irvine (USA), 3Pickup Family Neuroscience Institute, Hoag Memorial Hospital - Newport Beach (USA)

P54 An exploration of minimal clinically important differences for cognitive outcomes in preclinical and prodromal stages – implications for clinical AD trials
Emma Borland 1, Chris Edgar 2, Erik Stomrud 1, Nicholas Cullen 1, Oskar Hansson 1, Sebastian Palmqvist 1
1Lund University - Lund (Sweden), 2Cogstate - London (United Kingdom)

P57 The Amsterdam Instrumental Activities of Daily Living Questionnaire: Validation of a clinically meaningful outcome measure in asymptomatic and early symptomatic Alzheimer's disease
Mark Dubbelman 1, Merel Postema 1, Philip Scheltens 1, Wiesje Van Der Flier 1, 2, Sietske Sikkes 1, 3
1Alzheimer Center Amsterdam, Department Of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam Umc - Amsterdam (Netherlands), 2Department of Epidemiology and Biostatistics, Amsterdam UMC - Amsterdam (Netherlands), 3Department of Clinical, Neuro- & Developmental Psychology, Vrije Universiteit Amsterdam - Amsterdam (Netherlands)

P58 Monthly at-home computerized cognitive testing to detect diminished practice effects in preclinical Alzheimer's disease
Roos J. Jutten 1, Dorene M. Rentz 1, 2, Rebecca E. Amariglio 1, 2, Rachel F. Buckley 1, 2, 3, Michael J. Properzi 1, Paul Maruff 4, 5, Craig E. Stark 6, Michael A. Yassa 6, Keith A. Johnson 1, Reisa A. Sperling 1, 2, Kathryn V. Papp 7, 2
1Department Of Neurology, Massachusetts General Hospital, Harvard Medical School - Boston (USA), 2Department Of Neurology, Brigham and Women's Hospital, Harvard Medical School - Boston (USA), 3Melbourne School of Psychological Sciences, University of Melbourne - Melbourne (Australia), 4The Florey Institute Of Neuroscience And Mental Health - Melbourne, Vic (Australia) - Melbourne (Australia), 5Cogstate Ltd. - Melbourne (Australia), 6University Of California, Irvine - Irvine (USA), 7Department Of Neurology, Massachusetts General Hospital, Harvard Medical School - Boston (USA)

● POSTERS presented onsite

- P59** Use of app-based cognitive assessments during the COVID-19 pandemic: adherence and acceptability among cognitively normal older adults
Louisa Thompson¹, Karra Harrington², Nelson Roque³, Jennifer Strenger¹, Stephen Correia¹, Richard Jones¹, Stephen Salloway¹, Martin Sliwinski²
¹Brown University Medical School - Providence (USA), ²Penn State University - University Park (USA), ³University Of Central Florida - Orlando (USA)
- LP19** Boston Cognitive Assessment (BOCA) — a comprehensive self-administered smartphone- and computer-based at-home test for longitudinal tracking of cognitive performance
Andrey Vyshedskiy¹
Boston University - Boston (United States)
- LP20** Daily Boston Remote Assessment for Neurocognitive Health (BRANCH): Generating Short-Term
Daniel Soberanes¹, Stephanie Hsieh², Olivia Schneider¹, Rachel Buckley³, Michael Properzi², Emma Weizenbaum², Dorene Rentz³, Keith Johnson³, Reisa Sperling³, Rebecca Amariglio³, Kathryn Papp³
¹Brigham And Women's Hospital - Boston (United States), ²Massachusetts General Hospital - Boston (United States), ³Harvard Medical School - Boston (United States)
- LP21** Amyloid pathology but not ApoE4 status is permissive for tau-related hippocampal dysfunction
Emrah Duzel¹, Gabriel Ziegler¹, Hartmut Schutze¹, David Berron¹, Anne Maass¹, Glanz Wenzel¹, Michael Bury¹, Martin Reuter², Annika Spottke², Anja Schneider², Frederic Brosseron², Michael Heneka², Christoph Laske³, Oliver Peters⁴, Josef Priller⁴, Stefan Teipel⁵, Ingo Kiliman⁵, Jens Wiltfang⁶, Michael Wagner², Frank Jessen⁷
¹Dzne, Magdeburg - Magdeburg (Germany), ²Dzne, Bonn - Bonn (Germany), ³Dzne, Tübingen - Tübingen (Germany), ⁴Dzne, Berlin - Berlin (Germany), ⁵Dzne, Rostock - Rostock (Germany), ⁶Dzne, Göttingen (Germany), ⁷Dzne, Bonn/Cologne (Germany)

THEME

Epidemiology and clinical trials

- P61** Estimates of Frontotemporal Dementia by geographic regions
Cai Gillis¹, Flavia Nery¹, Ellen Huang¹, Elena Ratti¹, Dana Flanders², Cathy Lally³
¹Biogen - Cambridge, Ma (USA), ²Emory University, Rollins School Of Public Health, - Atlanta, Ga (USA), ³Epidemiologic Research & Methods, Llc - Atlanta, Ga (USA)
- P63** Distribution and baseline characteristics of participants with rapid progressing Alzheimer's Disease as measured by CDR-SB over 78 weeks in the National Alzheimer's Coordinating Center (NACC)
Cai Gillis¹, Nancy Maserejian¹, Ryan Miller¹
Biogen - Cambridge, MA (USA)
- LP22** Updated U.S. prevalence estimates accounting for racial and ethnic diversity for trials and therapies targeting mild cognitive impairment due to Alzheimer's disease (AD) and mild AD dementia
Cai Gillis¹, Mattia Gianinazzi¹, Mina Nejati¹, Nancy Maserejian¹
Biogen - Cambridge (United States)
- LP23** Urgency to treat before it's too late: Daily transitions to mild or moderate AD dementia in the US and Europe
Cai Gillis¹, Mina Nejati¹, Robin Thompson¹, Nancy Maserejian¹
Biogen - Cambridge (United States)

THEME

Digital health/E-trials

- P64** PROSPECT-AD- Population-based scReening Over SPEech for Clinical Trials in AD
Alexandra König¹, Nicklas Linz², Craig Ritchie³, Stefan Teipel⁴, Bruno Dubois⁵, Stephanie Bombois⁵, Marc Teichmann⁵, Sebastian Palmqvist⁶, Oskar Hansson⁶
¹Institut National De Recherche En Informatique Et En Automatique (inria). Stars Team. Sophia Antipolis. Valbonne. France. - Valbonne (France), ²Ki:elements, Saarbrücken, Germany. - Saarbrücken (Germany), ³Edinburgh Dementia Prevention, University Of Edinburgh, Edinburgh, Uk. - Edinburgh (United Kingdom), ⁴German Center For Neurodegenerative Diseases (dzne), Rostock, Germany; Department Of Psychosomatic And Psychotherapeutic Medicine, University Of Rostock, Rostock, Germany. - Rostock (Germany), ⁵Hôpital Universitaire Pitié Salpêtrière, Institut De La Mémoire Et De La Maladie D'alzheimer - Im2a, Paris, France. - Paris (France), ⁶Clinical Memory Research Unit, Department Of Clinical Sciences, Malmö, Lund University, Lund, Sweden - Lund (Sweden)
- P65** Optimizing paths for efficient use of digital health technologies in PD clinical trials: The Critical Path for Parkinson's 3DT initiative
Derek Hill¹, Martijn Müller², Jesse Cedarbaum³, Josh Cosman⁴, Lauren Oliva⁵, Mark Frasier⁶, Marissa Dockendorf⁷, Ariel Dowling⁸, Kirsten Taylor⁹, Emily Kunka¹⁰, Caldeira Caldeira¹¹, Ray Dorsey¹², Diane Stephenson²
¹University College Of London - London (France), ²Critical Path Institute - Tucson (USA), ³Coeruleus Clinical Sciences - Woodbridge (USA), ⁴Abbvie - Cambridge (USA), ⁵Biogen - Cambridge (USA), ⁶The Michael J. Fox Foundation - New York (USA), ⁷Merck - Philadelphia (USA), ⁸Takeda - Social Circle (USA), ⁹Roche - Basel (Switzerland), ¹⁰Ucb - San Francisco (USA), ¹¹Lundbeck - Copenhagen (Denmark), ¹²University Of Rochester - Rochester (USA)

● POSTERS presented onsite

- P66** Reducing sources of variability of Digital Health Technologies in clinical trials by adding environmental context
Derek Hill¹, Tri Thanh Tam Tran¹, Nicolas Defranoux¹, Alizee Devaux¹, Souleymen Sahnoun¹
Panoramic Digital Health - Grenoble (France)
- P67** Remote self-administration of cognitive tests in older adults with and without subjective cognitive decline using the BAC tablet-based ePRO platform
Alexandra Atkins¹, Mike Kraus¹, Matthew Welch¹, Joshua Yuan¹, Heather Stevens¹, Philip Harvey², Kathleen Welsh-Bohmer^{3,4}, Richard Keefe^{5,4}
¹Verasci - Durham (USA), ²University Of Miami Miller School Of Medicine - Miami (USA), ³Verasci - Durham (USA minor outlying islands) - Durham (USA), ⁴Duke University Medical Center - Durham (USA), ⁵Verasci - Durham (USA) - Durham (USA minor outlying islands)
- LP24** Evaluation of a remote speech-based AI system for detection of amyloid-confirmed prodromal Alzheimer's disease
Emil Fristed¹, Caroline Skirrow¹, Marton Meszaros¹, Lenain Raphael¹, Udeepa Meepegama¹, Jack Weston¹
Novoic - London (United Kingdom)
- LP25** AI-Driven Physician Referral Network Recruitment Initiative to Drive Volume, Speed and Efficiency for Clarity AD, a Phase 3 Trial in Early AD (ClarityAD)
Michael Stalder¹, Seth Goodman¹, Erin Beck¹, Russel Harris², Kate Tranotti², Chad Swanson²
¹SiteRx Inc. - New York, NY (United States), ²Eisai Inc. - Woodcliff Lake, NJ (United States)
- LP26** A First Look at Telemedicine Use for Pre-Screening in Alzheimer's Disease Clinical Trials During a Global Pandemic
Jennifer Mitolo¹, Elly Lee¹, Razyya Abdulmumin¹, Catherine Eng¹, Ralph Lee¹, Brenda Martinez¹
Irvine Clinical Research - Irvine (United States)

THEME

Health economics and clinical trials

- P68** Staying sharp beyond the age of 65 years: A social marketing approach to the promotion of cognitive health in Luxembourg
Mathilde Barbier¹, Anna Elena Kornadt¹, Carine Federspiel², Jean-Paul Steinmetz², Claus Vögele¹
¹University Of Luxembourg - Esch-Sur-Alzette (Luxembourg), ²Zitha - Luxembourg (Luxembourg)
- P69** Understanding Treatment Goals for Patients and Caregivers with Alzheimer's Disease Along the Continuum of the Disease Consideration in Clinical Trial Design
David Gomez-Ulloa D¹, M Chris Runken², Wilton I Rodriguez², Basilio Hernandez¹, E Anne Davis³, Paul Nisbet⁴
¹Grifols - Sant Cugat Del Vallès (Spain), ²Grifols Ssna - Research Triangle Park, Nc (USA), ³Xcenda - Palm Harbor (USA), ⁴One Research, Llc - Charleston, Sc (USA)
- LP27** Estimation of Long-term Care Utilization and Lifetime Distribution of Medical Cost for Dementia in Korea
Jun Hong Lee¹
National Health Insurance Service Ilsan Hospital - Goyang-Si (Korea, Republic of)

THEME

New therapies and clinical trials

- P70** Phase I single (SAD) and Multiple Ascending Dose (MAD) studies evaluating the safety, tolerability Pharmacokinetics (PK) and Pharmacodynamics (PD) of YTX-7739, a novel brain penetrant small molecule SCD inhibitor, in healthy subjects
Ajay Verma¹, Brigitte Robertson¹
Yumanity Therapeutics - Boston (USA)
- P71** Design of INFRONT-3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALO01 IN FTD-GRN
Sam Jackson¹, Michael Ward¹, Yijie Liao¹, Brian Mangal¹, Felix Yeh¹, Whedy Wang¹, Robert Paul¹
Alector - South San Francisco, Ca (USA)
- P72** External Counterpulsation (Renew™ NCP-5 Device) for the Treatment of MCI due to Alzheimer's Disease or Mild Dementia of the Alzheimer's Type: A Pivotal Trial
Patrick Moriarty¹, Lauryn Gorby¹, David Salat², Jeffrey Burns³, Tom Moreno⁴, Jonathan Helfgott⁴
¹University Of Kansas Medical Center - Kansas City (USA), ²Harvard Medical School - Boston (USA), ³Kansas University Alzheimer's Disease Center - Kansas City (USA), ⁴Renew Research - Farmington Hills (USA)
- LP28** A Phase 1a, Randomized, Placebo-controlled, Single and Multiple Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of Novel Regenerative Therapeutic NNI-362
Judith Kelleher-Andersson¹, Esther Yoon², Carol Green³, Claire Mcfarlane³, Raymond Turner⁴
¹Neuronascent, Inc. - Mountain View (United States), ²California Clinical Trials Medical Grp - Glendale (United States), ³Sri - Menlo Park (United States), ⁴Georgetown University - Washington, D.c. (United States)

● POSTERS presented onsite

LP29

BET-inhibition by Apabetalone and Cognitive Effects: A Prespecified MoCA Analysis Nested in the BETonMACE Randomized Controlled Trial

Jeffrey Cummings¹, Gregory Schwartz², Stephen Nicholls³, Aziz Khan⁴, Christopher Halliday⁴, Peter Toth⁵, Michael Sweeney⁶, Jan Johansson⁶, Norman Wong⁴, Ewelina Kulikowski⁴, Kamyar Kalantar-Zadeh⁷, Kenneth Lebioda⁴, Henry Ginsberg⁸, Bengt Winblad⁹, Henrik Zetterberg^{10,11,12}, Kausik Ray¹³

¹Chambers-Grundy Center For Transformative Neuroscience, Department Of Brain Health, School Of Integrated Health Sciences, University Of Nevada Las Vegas (unlv) - Las Vegas (United States), ²Division Of Cardiology, University Of Colorado School Of Medicine - Aurora (United States), ³Victorian Heart Institute, Monash University - Melbourne (Australia), ⁴Resverlogix Corp. - Calgary (Canada), ⁵Cicarrone Center For The Prevention Of Cardiovascular Disease, Johns Hopkins University School Of Medicine - Baltimore (United States), ⁶Resverlogix Corp. - California (United States), ⁷Division Of Nephrology And Hypertension, University Of California Irvine - California (United States), ⁸Department Of Medicine, Vagelos College Of Physicians And Surgeons, Columbia University, New York, Ny Department Of Neurobiology - New York (United States), ⁹Care Sciences And Society, Center For Alzheimer Research, Division Of Neurogeriatrics, Karolinska Institutet, Solna, Sweden, And Karolinska University Hospital, Theme Inflammation And Aging, Huddinge - Stockholm (Sweden), ¹⁰Department Of Psychiatry And Neurochemistry, Institute Of Neuroscience And Physiology, The Sahlgrenska Academy At The University Of Gothenburg - Mölndal (Sweden), ¹¹Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital - Mölndal (Sweden), ¹²UK Dementia Research Institute at UCL and Department of Neurodegenerative Disease, UCL Institute of Neurology - London (United Kingdom), ¹³Imperial Centre For Cardiovascular Disease Prevention, Imperial College - London (United Kingdom)

LP31

Novel therapeutic efficacy of Galectin-3 antibody for treating Alzheimer's disease

Suhail Rasool¹, Pooja Patel¹, Jenny Johansson¹, Taufeeq Ahmed¹, Ludmila Voloboueva¹, Sangmi Lee¹, Catherine Gordon¹, Kyungjoon Lee¹, Dongxu Sun¹

Truebinding Inc. - Foster City (United States)

THEME

Proof of concept/Translational research for Alzheimer Drug Development interventions

P73

Alzheimer's disease prevention Within Reach by 2025: Targeted-Risk-AD-Prevention (TRAP) Strategy

Francesca Vitali^{1,2,3}, Gregory L. Branigan^{1,4,5}, Roberta D. Brinton^{1,6,2}

¹Center For Innovation In Brain Science, University Of Arizona - Tucson (USA), ²Department of Neurology, University of Arizona - Tucson (USA), ³Center for Biomedical Informatics and Biostatistics, University of Arizona - Tucson (USA), ⁴Department of Pharmacology - Lawrence (USA), ⁵MD-PhD training program, College of Medicine, University of Arizona - Tucson (USA), ⁶Department of Pharmacology - Tucson (USA)

LP32

Probing Gut-Brain Links in Alzheimer's Disease with Rifaximin

Paul Suhocki¹, James Ronald¹, Anna Mae Diehl¹, David Murdoch¹, Murali Doraiswamy¹

Duke University - Durham (United States)



On demand
scientific program
presented
on the digital platform

● Tuesday,
NOVEMBER 9

Presentations will be available
from 8:00 am USA Eastern Standard Time



SYMPOSIA

RS1 Cannabinoids for neuropsychiatric symptoms of Alzheimer's: trial designs and outcomes

Chair: Paul Rosenberg, Johns Hopkins Hospital, Baltimore, MD (USA)

Nabilone for the treatment of agitation in Alzheimer's disease

Krista Lanctôt, Sunnybrook Research Institute - Toronto (Canada)

Assessing the efficacy and safety of synthetic THC (Dronabinol) for agitation and CBD for anxiety in Alzheimer's dementia

Brent Forester, Mclean Hospital - Belmont, MA (USA)

Life's end Benefits of Cannabidiol and Tetrahydrocannabinol (LiBBY) Trial

Jacobo Mintzer, Roper St. Francis Healthcare, Charleston, SC (USA)

RS2 The Next Generation of Speech Biomarkers for the Early Detection of Alzheimer's Disease

Chair: Emil Fristed, Novoic - London (United Kingdom)

Validation of a novel fully automated story recall task for repeated remote high-frequency administration

Caroline Skirrow, Novoic, Bristol (United Kingdom)

How clinically informed deep learning can make better speech biomarkers

Jack Weston, Novoic - London (United Kingdom)

A harmonized speech dataset for Alzheimer's disease biomarker development: study design of the Diagnostics Accelerator Speech Consortium Study

Lampros Kourtis, Tufts University Medical Center, Gates Ventures, Circadic - Boston, MA (USA)

RS3 Back to the Future: Emerging Opportunities to Treat Basal Forebrain Cholinergic Neuron (BFCN) Dysfunction in Alzheimer's Disease (AD)

Chair: Marwan Sabbagh, Cleveland Clinic Lou Ruvo Center For Brain Health Las Vegas, NV, (USA)

The Contribution of BFCN Dysfunction and Degeneration to Disease Expression and Progression in AD

Ole Isacson, Neuroregeneration Research Institute at Mclean Hospital - Belmont and Harvard Medical School - Boston, MA (USA)

Mechanisms of, and Preclinical Results with Novel Approaches to Treating, BFCN Dysfunction and Degeneration

Ralph Nixon, Center for Dementia Research, Nathan S. Kline Institute for Psychiatric Research - Orangeburg and NYU Langone Health - New York, NY (USA)

Clinical Results with Novel Approaches that Reverse BFCN Dysfunction

John Alam, EIP Pharma, Inc. - Boston, MA (USA)

LATE BREAKING ORAL COMMUNICATIONS

LB1 - The probabilistic model of Alzheimer disease: the amyloid hypothesis revised

Giovanni Frisoni¹, Daniele Altomare¹, Dietmar Thal², Federica Ribaldi¹, Rik Van Der Kant³, Rik Ossenkoppele³, Kaj Blennow⁴, Jeffrey Cummings⁵, Cornelia Van Duijn⁶, Peter M. Nilsson⁷, Pierre-Yves Dietrich⁸, Philip Scheltens³, Bruno Dubois⁹

¹University Of Geneva - Geneva (Switzerland), ²University Of Leuven - Leuven (Belgium), ³Amsterdam Umc - Amsterdam (Netherlands),

⁴University Of Gothenburg - Gothenburg (Sweden), ⁵University Of Nevada Las Vegas - Las Vegas (United States), ⁶Erasmus University Medical

Center - Rotterdam (Netherlands), ⁷Skåne University Hospital - Malmö (Sweden), ⁸Geneva University Hospitals - Geneva (Switzerland), ⁹Sorbonne Université - Paris (France)

● Tuesday,
NOVEMBER 9

Presentations will be available
from 8:00 am USA Eastern Standard Time



LBR2 - Baseline Embark data from Emerge, Engage, and Prime participants in the Embark re-dosing study

Sharon Cohen¹, Christopher Van Dyck², Catherine Mummery³, Anton Porsteinsson⁴, Jessica Kong⁵, Ryan Miller⁵, Annie Racine⁵, John O'gorman⁵, Samantha Budd Haerberlein⁵, Salloway Stephen⁶

¹Toronto Memory Program - Toronto (Canada), ²Alzheimer's Disease Research Unit, Yale School Of Medicine - New Haven (United States),

³Dementia Research Centre, Queen Square Institute Of Neurology, University College London - London (United Kingdom), ⁴University Of Rochester School Of Medicine And Dentistry - Rochester (United States), ⁵Biogen - Cambridge (United States), ⁶Alpert Medical School of Brown University - Providence (United States)

LBR3 - National Alzheimer's Disease Clinical Trial Sites' Accommodations to the COVID-19 Pandemic

Elizabeth Rhodus¹, Paul Aisen², Joshua Grill³, Dorene Rentz^{4,5}, Reisa Sperling^{4,5}, Ronald Petersen⁶, Stephen Salloway⁷, Doris Pierce⁸, Rema Raman⁹

¹Sanders-Brown Center On Aging, University Of Kentucky - Lexington (United States), ²Alzheimer's Therapeutic Research Institute, University

Of Southern California San Diego - San Diego (United States), ³University Of California, Irvine - Irvine (United States), ⁴Massachusetts General Hospital, Harvard Medical School - Boston (United States), ⁵Brigham and Women's Hospital, Harvard Medical School - Boston (United States), ⁶Department Of Neurology, Mayo Clinic - Rochester (United States), ⁷Butler Hospital And Brown University - Providence (United States), ⁸Eastern Kentucky University - Richmond (United States), ⁹Alzheimer's Therapeutic Research Institute, University Of Southern California, San Diego - San Diego (United States)

LBR4 - Defining a standardized MRI acquisition protocol to be proposed to ICARE AD-US sites for baseline and ARIA monitoring

Tammie, L. S. Benzinger¹, Frederik Barkhof², Alex Rovira³, Tobias Kober⁴, Christopher, T. Whitlow⁵, Michael Smith⁶, Christina, M. Grassi⁶, Elizabeth Fisher⁶

¹Washington University School Of Medicine, Department Of Neurology - St. Louis (United States), ²Department Of Radiology And Nuclear Medicine, Amsterdam Neuroscience, Amsterdam Umc, Vrije Universiteit - Amsterdam (Netherlands), ³Section Of Neuroradiology, Vall D'hebron University Hospital - Barcelona (Spain), ⁴Advanced Clinical Imaging Technology, Siemens Healthcare - Lausanne (Switzerland), ⁵Wake Forest School Of Medicine - Winston-Salem (United States), ⁶Biogen - Cambridge (United States)

LBR5 - Top-line results from TANGO, a Phase 2 study of gosuranemab in participants with mild cognitive impairment due to Alzheimer's disease and mild Alzheimer's disease

Melanie Shulman¹, Raj Rajagovindan¹, Jessica Kong¹, John O'gorman¹, Louis Viollet¹, Ellen Huang¹, Heike Hering¹, Elena Ratti¹, Danielle Graham¹, Samantha Budd Haerberlein¹
Biogen - Cambridge (United States)

LBR6 - Oral treatment with OLX-07010, a small molecule inhibitor of tau self-association, reduced tau aggregation to baseline in a therapeutic study of aged tau P301L JNPL3 mice

James Moe¹, Patricia Lopez², Heidy Jimenez-Bravar³, Adrien Leslie³, J Eun³, Adam Wolin³, Jeremy Koppel³, Peter Davies³, Dhruv Patel², Eliot Davidowitz²

¹Oligomerix, Inc. - White Plains (United States), ²Oligomerix, Inc. - Bronx (United States), ³Feinstein Institutes For Medical Research - Manhasset (United States)

LBR7 - Analyzing the CSF proteome to support decisions in an AD clinical trial program

Ian Pike¹, Sasa Koncarevic², Juliane Weisser², Michael Bremang², R J Tesi³, C J Barnum³

¹Proteome Sciences Plc - London (United Kingdom), ²Proteome Sciences R&D GmbH & Co Kg - Frankfurt (Germany), ³Inmunebio - Boca Raton (United States)

LBR8 - Prediction of brain amyloid pathology using plasma Aβ42/40 ratio measured using the C2N PrecivityADTM test in the Mission AD study samples

David Verbel¹, Michelle Gee², June Kaplow¹, Michio Kanekiyo¹, Michael Irizarry¹, Shobha Dhadda¹, Akihiko Koyama¹, Tim West³, Matt Meyer³, Kris Kirmess³

¹Eisai Inc. - Woodcliff Lake (United States), ²Eisai Ltd. - Hatfield (United Kingdom), ³C2N Diagnostics - St. Louis (United States)

LBR9 - Evaluation of tau deposition using 18F-PI-2620 PET in MCI and early AD – a MissionAD tau sub-study

Santiago Bullich¹, Andre Mueller¹, Susan De Santi², Norman Koglin¹, Stephen Krause², June Kaplow², Michio Kanekiyo², Núria Roé-Vellvé¹, Audrey Perrotin¹, Aleksandar Jovalekic¹, David Scott³, Michelle Gee², Andrew Stephens¹, Michael Irizarry²

¹Life Molecular Imaging (Germany), ²Eisai (United States), ³Bioclinica (United States)

● Tuesday,
NOVEMBER 9

Presentations will be available
from 8:00 am USA Eastern Standard Time



LBR10 - The impact of the COVID-19 pandemic on cognitive health

Helen Brooker¹, Vincent Hayman², Dag Aarsland³, Byron Creese², Clive Ballard², Anne Corbett²

¹Exeter University Medical School - Exeter (United Kingdom) - Exeter (United Kingdom), ²Exeter University Medical School - Exeter (United Kingdom), ³Department Of Old Age Psychiatry, Institute Of Psychiatry, Psychology & Neuroscience, Maurice Wohl Clinical Neuroscience Institute, King's College London - London (United Kingdom)

LBR11 - Utility of plasma Aβ1-42/Aβ1-40 as a screening tool is limited due to lack of robustness

Christina Rabe¹, Tobias Bittner^{1,2}, Alexander Jethwa³, Ivonne Suridjan⁴, Ekaterina Manuilova³, Henrik Zetterberg^{5,6,7}, Kaj Blennow^{5,6}, Oskar Hansson^{8,9}

¹Genentech, Inc. - South San Francisco (United States), ²F. Hoffmann-La Roche Ltd - Basel (Switzerland), ³Roche Diagnostics GmbH - Penzberg (Germany), ⁴Roche Diagnostics International Ltd - Rotkreuz (Switzerland), ⁵Department Of Psychiatry And Neurochemistry, Institute Of Neuroscience And Physiology, The Sahlgrenska Academy At The University Of Gothenburg - Mölndal (Sweden), ⁶Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital - Mölndal (Sweden), ⁷Department of Neurodegenerative Disease, UCL Institute of Neurology and UK Dementia Research Institute at UCL - London (United Kingdom), ⁸Clinical Memory Research Unit, Department Of Clinical Sciences Malmö, Lund University - Malmö (Sweden), ⁹Memory Clinic, Skåne University Hospital - Malmö (Sweden)

LBR12 - Polygenic risk scores can predict early cognitive impairment as measured by the Preclinical Alzheimer Cognitive Composite (PACC) score in the ADNI cohort

Qian Gao¹, Richard Pither¹, Paula Daunt¹, Alex Gibson¹

Cytox Ltd - Oxford (United Kingdom)

LBR13 - Association of serum degraded tau biomarkers with preclinical dementia: a Mendelian randomization study

Tobias Melton Axelsen^{1,2,3}, Cecilie Liv Bager⁴, Morten Asser Karsdal⁴, Kim Henriksen⁴, Man-Hung Eric Tang⁴

¹Sanos Clinic - Herlev (Denmark), ²Department of Biomedical Science - Copenhagen (Denmark), ³Nordic Bioscience A/S - Herlev (Denmark), ⁴Nordic Bioscience A/S - Herlev (Denmark)

LBR14 - 18F-APN-1607 Tau PET in Progressive Supranuclear Palsy-Like Symptoms Caused by TBK1 Mutations

Feng-Tao Liu¹, Tzu-Chen Yen², Chuan-Tao Zuo¹, Chen Yan¹, Jian Wang¹

¹Huashan Hospital, Fudan University (China), ²Aprinoia Therapeutics Co., Ltd, Suzhou (China)

● Wednesday,
NOVEMBER 10

Presentations will be available
from 8:00 am USA Eastern Standard Time



RS4 Innovative Approaches and Technologies Shaping the Future of Alzheimer's Clinical Trials

Chair: Jeffrey Cummings, University of Nevada - Las Vegas, NV (USA)

Prognostic Covariate Adjustment (PROCOVA) enables smaller, more powerful trials while reducing uncertainty and maintaining control of type I error

Alejandro Schuler, *Unlearn.ai, Stanford University - San Francisco, CA (USA)*

Design and implementation of novel trial designs: Harnessing short-term learning curves (STLCs) to accelerate early detection and tracking in Alzheimer's disease secondary prevention trials

Kathryn Papp, *Harvard Medical School; Brigham And Women's Hospital - Boston, MA (USA)*

Design and implementation of novel trial approaches: New imaging markers for clinical trials

Steven Chance, *Oxford Brain Diagnostics - Oxford (United Kingdom)*

ROC1 - Comparing remote versus in-clinic clinical outcome assessments in the Tauriel study of semorinemab in early AD: The COVID-19 experience

Paul Manser¹, Mira Blendstrup¹, Nia Sengupta¹, Karen Pickthorn¹, Enrique Gaspar², Winnie Leung¹, Mayumi Thompson¹, Edmond Teng¹, Rajesh Menon¹

¹Genentech, Inc. - South San Francisco, CA (USA), ²Medavante-Prophase - Hamilton, NJ (USA)

ROC2 - The utility of using version 3 of the Alzheimer's Disease Research Centers' neuropsychological test battery for prevention trials

Kwun Chuen Gary Chan¹, Hiroko H. Dodge², Lisa L. Barnes³, Fan Xia⁴, Walther A. Kukull⁴, Andrew J. Saykin⁵

¹University Of Washington-Seattle, WA (USA), ²Oregon Health And Science University - Portland, OR (USA), ³Rush University - Chicago, IL (USA), ⁴University of Washington - Seattle, WA (United States), ⁵Indiana University - Indianapolis, IN (USA)

ROC3 - Allopregnanolone as a Regenerative Therapeutic for Alzheimer's: Exploratory Phase 1 Neuroimaging MRI Outcomes

Adam C. Raikes¹, Dawn Matthews², Gerson Hernandez¹, Yonggang Shi³, Meng Law⁴, Lon Schneider⁵, Roberta Brinton¹

¹Center For Innovation In Brain Science, University of Arizona - Tucson, AZ (USA), ²ADM Diagnostics, Inc - Northbrook, IL (USA), ³USC Stevens Neuroimaging and Informatics Institute, University of Southern California - Los Angeles, CA (USA), ⁴Monash University - Melbourne (Australia), ⁵Keck School Of Medicine of The University Of Southern California - Los Angeles, CA (USA)

ROC4 - Early detection of Alzheimer's disease with BrainSee, the FDA Breakthrough software medical device

Thomas Liebmann¹, Elham Khosravi², Pavan Krishnamurthy³, Padideh Kamali-Zare³, Kaveh Vejdani³

¹Darmiy, Inc. - Penzberg (Germany), ²Darmiy, Inc. - Berlin (Germany), ³Darmiy, Inc. - San Francisco, CA (USA)

ROC5 - Evaluating the contribution of image-derived features for predicting rate of cognitive decline in a large cohort (including 6 clinical trials; n=3,339) of early AD patients

Derrek Hibar¹, Balazs Toth¹, Christopher Galli², Tobias Bittner², Christina Rabe¹, David Clayton¹

¹Genentech - South San Francisco, CA (USA), ²Roche - Basel (Switzerland)

ROC6 - Using a symmetric warfield in a deep-learning framework for Jacobian integration to estimate brain atrophy

Marina Papoutsis^{1,2}, Bianca De Blasi¹, Richard Joules¹, Michael Reinwald¹, Robin Wolz^{1,3}

¹Ixico Plc - London (United Kingdom), ²University College London - London (United Kingdom), ³Imperial College London - London (United Kingdom)

ROC7 - Assessing 11 β -HSD1 in vivo occupancy by Xanamem® using 11C-TARACT PET

Christopher C. Rowe¹, Victor L. Villemagne², Vincent Doré³, Lee Chong¹, Rachel Mulligan¹, Svetlana Bozinovski¹, Rodney Guzman¹, Michael Kassiou⁴, Jack Taylor⁵, Tamara Miller⁵

¹Austin Health - Melbourne (Australia), ²University of Pittsburgh - Pittsburgh, OH (USA), ³Csiro - Melbourne (Australia), ⁴University Of Sydney - Sydney (Australia), ⁵Actinogen Medical Ltd - Sydney (Australia)

● Wednesday,
NOVEMBER 10

Presentations will be available
from 8:00 am USA Eastern Standard Time



ROC8 - Characteristics of subjects with discordant amyloid status between visual read and centiloid from the Phase 2 clinical study of Tilavonemab in early Alzheimer's disease

Eddie Stage¹, Dustin Wooten¹, Ziyi Jin¹, Charles Locke¹, Jacob Hesterman², John Seibyl², Hana Florian¹, Robert Comley¹, Qi Guo¹

¹Abbvie Inc. - North Chicago (United States), ²Invicro - New Haven (United States)

ROC10 - Plasma Neurofilament Light chain and Phosphorylated tau217 in Patients with Type 2 Diabetes Treated with GLP-1 Receptor Agonist Dulaglutide in the REWIND Cardiovascular Outcomes Trial

Jonathan M Wilson¹, Hui-Rong Qian¹, Courtney Irelan¹, Hannah Badger¹, Jeffrey L Dage¹, Kevin L Duffin¹, Dawn A Brooks¹, Hertz C Gerstein², M Angelyn Bethel¹

¹Eli Lilly and Company - Indianapolis, IN (USA), ²Population Health Research Institute - Hamilton (Canada) - Hamilton (Canada)

● **Thursday,**
NOVEMBER 11

Presentations will be available
from 8:00 am USA Eastern Standard Time



ORAL COMMUNICATIONS



ROC11 - Maximizing precision and power in Alzheimer's disease trials: how and when to select the most prognostic baseline variables

Michael Rosenblum ¹, [Elizabeth Colantuoni](#) ¹, Melody Dehghan ¹, Michela Gallagher ¹, Arnold Bakker ¹
Johns Hopkins University - Baltimore, MD (USA)

ROC12 - Baseline characteristics of the GRADUATE studies: Phase III randomized, placebo-controlled studies investigating subcutaneous gantenerumab in participants with early Alzheimer's disease

[Christopher Lane](#) ¹, Szofia Bullain ², Monika Baudler ², Angeliki Thanasopoulou ², Paul Delmar ², Mercè Boada ^{3,4}, Timo Grimmer ⁵, Diana Kerwin ⁶, Paulo Fontoura ², Geoffrey A Kerchner ², Rachelle S Doody ^{2,7}

¹Roche Products Ltd - Welwyn Garden City (United Kingdom), ²F. Hoffmann-La Roche - Basel (Switzerland), ³Fundació Ace, Barcelona Alzheimer Treatment And Research Center - Barcelona (Spain), ⁴Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III - Madrid (Spain), ⁵Klinikum Rechts Der Isar, Technical University Of Munich, School Of Medicine - Munich (Germany), ⁶Kerwin Medical Center - Dallas, TX (USA), ⁷Genentech, Inc. - South San Francisco, CA (USA)

ROC13 - T2 Protect AD: Results of a 48-Week Randomized Clinical Trial of Troriluzole in Mild-to-Moderate Alzheimer's Disease

[Howard Feldman](#) ¹, Qiu Yuqi ¹, Karen Messer ¹, Stephen Kaplita ², Ronald Thomas ¹, Branko Huisa-Garate ¹, James Brewer ¹, Lia Donahue ², Vladimir Coric ², Brianna Askew ¹, Gregory Jicha ³, Christopher Van Dyck ⁴, Mark Brody ⁵, Jonathan Drake ⁶, Gabriel Leger ¹, Anton Porsteinsson ⁷, Suzanne Hendrix ⁸, Diane Jacobs ¹, David Salmon ¹, Irfan Qureshi ²

¹University Of California San Diego - La Jolla, CA (USA), ²Biohaven Pharmaceuticals - New Haven, CT (USA), ³University Of Kentucky College of Medicine - Lexington (USA), ⁴Yale University School of Medicine - New Haven, CT (USA), ⁵Brain Matters Research - Delray Beach, FL (USA), ⁶Alzheimer's Disease And Memory Disorders Center at Rhode Island Hospital - Providence, RI (USA), ⁷University Of Rochester School Of Medicine And Dentistry - Rochester, MN (USA), ⁸Pentara Corporation - Millcreek, UT (USA)

ROC14 - Brainshuttle AD: A Phase Ib/Ia Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RG6102 in Participants with Prodromal or Mild-to-Moderate Alzheimer's Disease

[Luka Kulic](#) ¹, Annamarie Vogt ¹, Fabien Alcaraz ¹, Philip Barrington ¹, Maddalena Marchesi ¹, Gregory Klein ¹, Ruth Crony ¹, David Agnew ¹, João A Abrantes ¹, Paul Jordan ¹, Hanno Svoboda ¹

F. Hoffmann-La Roche Ltd - Basel (Switzerland)

ROC15 - PK/PD modeling framework to inform the clinical development of RG6102, an amyloid-targeting investigational drug with enhanced brain penetration properties

[João A Abrantes](#) ¹, Hans Peter Grimm ¹, Carsten Hofmann ¹, Simon Buatois ¹, Sébastien Jolivet ¹, Nicolas Frey ¹, Hanna Silber Baumann ¹, Hanno Svoboda ¹, Luka Kulic ¹

Roche Innovation Center - Basel (Switzerland)

ROC16 - Results of A Phase 1, Randomized, Blinded, Placebo-Controlled, Single-Ascending-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB076 in Healthy Volunteers and Subjects With Alzheimer's Disease

[Elena Ratti](#) ¹, Hua Carroll ¹, Lin Lin ¹, Carrie Rubel ¹, Alexis Ang ¹, John O'gorman ¹, Matthew Ross ¹, Kumar Kandadi Muralidharan ¹, Danielle Graham ¹, Julie Czerkowicz ¹, Ellen Huang ¹, Jaren Landen ¹, Samantha Budd Haerberlein ¹

Biogen - Cambridge (United States)

● Friday,
NOVEMBER 12

Presentations will be available
from 8:00 am USA Eastern Standard Time



ROC17 - ACI-35.030, a novel anti-phospho-Tau vaccine for the treatment of Alzheimer's Disease: Interim Phase 1b/2a data on safety, tolerability and immunogenicity

Johannes Streffer 1, 2, Bénédicte Le 1, Olivier Sol 1, Marija Vukicevic 1, Emma Fiorini 1, Eva Gollwitzer 1, Valérie Hliva 1, Julien Mermoud 1, David Hickman 1, Julian Gray 1, Antonio Melo Dos Santos 1, Nicolas Piot 1, Julien Rongère 1, Andrea Pfeifer 1, Marie Kosco-Vilbois 1, Philip Scheltens 3

1AC Immune - Lausanne (Switzerland), 2Department of Biomedical Sciences, University of Antwerp - Antwerpen (Belgium), 3VUMC - Amsterdam (Netherlands)

ROC18 - Characterization of the disease course during transitioning from MCI due to AD to dementia predicts follow-up performance and reveals possible contribution of reduced hippocampal atrophy on the intervention effect in the LipiDiDiet trial

Tobias Hartmann 1, 2, Alina Solomon 3, 4, 5, Pieter Visser 6, 7, Floor Van Oudenhoven 8, 9, 10, Dimitris Rizopoulos 8, 9, Suzanne Hendrix 11, Kaj Blennow 12, 13, Miia Kivipelto 3, 4, 5, Hilka Soininen 3, 14

1Deutsches Institut Für Demenz Prävention (didp), Medical Faculty, Saarland University - Homburg (Germany), 2Department of Experimental Neurology, Saarland University - Saarbrücken (Germany), 3Department Of Neurology, Institute Of Clinical Medicine, University Of Eastern Finland - Kuopio (Finland), 4Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institute - Huddinge (Sweden), 5Clinical Trials Unit, Theme Aging, Karolinska University Hospital Kuopio - Huddinge (Sweden), 6Department Of Psychiatry And Neuropsychology, Alzheimer Center Limburg, University Of Maastricht - Maastricht (Netherlands), 7Department of Neurology, Alzheimer Center, VU University Medical Center - Amsterdam (Netherlands), 8Department Of Biostatistics, Erasmus Mc - Rotterdam (Netherlands), 9Department of Epidemiology, Erasmus MC - Rotterdam (Netherlands), 10Danone Nutricia Research, Utrecht - Utrecht (Netherlands), 11Pentara Corporation, Milcreek - Millcreek, UT (USA), 12Department Of Psychiatry And Neurochemistry, Institute Of Neuroscience And Physiology, The Sahlgrenska Academy At University Of Gothenburg - Mölndal (Sweden), 13Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital - Mölndal (Sweden), 14Neurocenter, Department of Neurology, Kuopio University Hospital - Kuopio (Finland)

ROC19 - Phase 2 Study of Tilavonemab, an Anti-tau Antibody, in Early Alzheimer's Disease

Hana Florian 1, Deli Wang 1, Qi Guo 1, Ziyi Jin 1, Nahome Fisseha 1, Beatrice Rendenbach-Mueller 1

Abbvie, Inc. - North Chicago, IL (USA)

ROC20 - The epigenetic modulator apabetalone decreases neuroinflammation in blood brain barrier cell models and LPS-treated mice

Sylwia Wasiak 1, Li Fu 1, Emily Daze 1, Dean Gilham 1, Brooke Rakai 1, Stephanie Stotz 1, Laura Tsujikawa 1, Christopher Sarsons 1, Ravi Jahagirdar 1, Norman Wong 1, Michael Sweeney 2, Jan Johansson 2, Ewelina Kulikowski 1

1Resverlogix Corp - Calgary (Canada), 2Resverlogix Corp - San Francisco, CA (USA)

ROC21 - Effect of Plasma Exchange with Albumin Replacement in Alzheimer's Treatment on Ability to Perform Activities of Daily Living (ADL)

Richard B Lipton 1, Walter F Stewart 2, Lauren Podger 3, David Gomez-Ulloa 4, M Chris Runken 5, Miquel Barcelo 4, Carlota Grifols 4, Daniel Serrano 6

1 Albert Einstein College Of Medicine - New York, NY (USA), 2 Medcurio Inc - Oakland, CA (USA), 3 Open Health Group - Marlow (United Kingdom), 4 Grifols - Sant Cugat Del Vallès (Spain), 5 Grifols Sna - Research Triangle Park, NC (USA), 6 Open Health Group - Bethesda, MD (USA)

ROC22 - Baseline Characteristics for CLARITY-AD: A Phase 3 Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study Evaluating Lecanemab (BAN2401) in Early Alzheimer's

Shau Yu Lynch 1, Michelle Gee 2, Michio Kanekiyo 1, Tanya Bogoslovsky 1, June Kaplow 1, Shobha Dhadha 1, Michael Irizarry 1, David Li 1, Vicki Taylor 2, Mark Hodgkinson 1, Masaki Nakagawa 3, Chad Swanson 1

1Eisai Inc - Woodcliff Lake (USA), 2Eisai Ltd - Hatfield (United Kingdom), 3Eisai Co., Ltd - Tokyo (Japan)

ROC23 - A Stepwise Tier-Based Approach for Determining Patient Eligibility in CLARITY AD: A Phase 3 Placebo-Controlled, Double-Blind Study to Confirm the Safety and Efficacy of Lecanemab (BAN2401) 10 mg/kg Biweekly in Patients with Early Alzheimer's Disease

Shau Yu Lynch 1, Michelle Gee 2, Michio Kanekiyo 1, Michael Smith 3, Tanya Bogoslovsky 1, June Kaplow 1, Shobha Dhadha 1, Michael Irizarry 1, Vicki Taylor 2, Mark Hodgkinson 1, Masaki Nakagawa 4, Chad Swanson 1

1Eisai Inc - Woodcliff Lake (USA), 2Eisai Ltd - Hatfield (United Kingdom), 3Worldwide Clinical Trials - Research Triangle (USA), 4Eisai Co., Ltd - Tokyo (Japan)



POSTER PRESENTED REMOTELY

- **THEME**
AD clinical trials and COVID-19
- **THEME**
Animal model and clinical trial
- **THEME**
Behavioral disorders and clinical trials
- **THEME**
Clinical trials: cognitive and functional endpoints
- **THEME**
Clinical trials: imaging
- **THEME**
Clinical trials: biomarkers including plasma
- **THEME**
Clinical trials: methodology
- **THEME**
Clinical trials: results
- **THEME**
Cognitive assessment and clinical trials
- **THEME**
Digital health/E-trials
- **THEME**
Health economics and clinical trials
- **THEME**
Epidemiology and clinical trials
- **THEME**
New therapies and clinical trials
- **THEME**
Proof of concept/Translational research for Alzheimer Drug Development interventions

RP1

RP2

RP3 - LRP2

RP4

RP5 to LRP2bis

RP7 to LRP5

RP14 to LRP9

RP18 to LRP10

P55 to P60

RP26 to LRP13

RP33 to LRP11

RP34 to P62

RP39 to RP41

RP42 to LRP14

Posters presented remotely

All posters presented remotely will also be available at all times on the digital platform to be viewed by participants attending remotely or in-person.



POSTERS presented remotely

THEME

AD clinical trials and COVID-19

RP1

Dementia research participation and patient preferences during the COVID-19 pandemic

Lucianne Dobson 1, Floey Urban 1, Ross Paterson 1, Sebastian Crutch 1, Suzie Barker 1, [Cath Mummy](#)¹

Dementia Research Centre, National Hospital For Neurology And Neurosurgery, Queen Square, University College London And University College London Hospital - London (United Kingdom)

THEME

Animal model and clinical trial

RP2

FAM171A2 associates with Alzheimer's disease by functioning as a carrier that facilitates A β 42 clearance through cerebral endothelium

Han Sida 1, Yu Jintai 1, Cui Mei 1, Dong Qiang 1

Department Of Neurology, Huashan Hospital, Fudan University - Shanghai (China)

THEME

Behavioral disorders and clinical trials

RP3

Pharmacological treatment of neuropsychiatric symptoms of dementia: a network meta- analysis

[Jin-Tai Yu](#), *Huashan Hospital, Fudan University - Shanghai (China)*

LRP1

Beneficial Effects of Masupirdine on Psychosis in Patients with Alzheimer's disease, Addressing Limitations of Current Pharmacological Interventions

[Ramakrishna Nirogi](#) 1, Anil Shinde 1, Abdul Rasheed Mohammed 1, Vinod Kumar Goyal 1, Vijay Benade 1, Veera Raghava Chowdary Palacharla 1, Ramkumar Subramanian 1, Renny Abraham 1, Pradeep Jayarajan 1, Jyothsna Ravula 1, Satish Jetta 1

Suven Life Sciences Ltd - Hyderabad (India)

LRP2

Pimavanserin treatment of hallucinations and delusions in patients with Parkinson's disease dementia: post hoc analysis of the HARMONY trial

[Daniel Weintraub](#) 1, Alberto Espay 2, Vibhash Sharma 3, Pierre Tariot 4, Victor Ablner 5, Sanjeev Pathak 5, Srdjan Stankovic 5

1Departments Of Psychiatry And Neurology, Perelman School Of Medicine At The University Of Pennsylvania - Philadelphia (United States), 2Gardner Family Center For Parkinson's Disease And Movement Disorders, Department Of Neurology, University Of Cincinnati - Cincinnati (United States), 3Department Of Neurology, University Of Kansas Medical Center - Kansas City (United States), 4Banner Alzheimer's Institute And University Of Arizona College Of Medicine - Phoenix (United States), 5Acadia Pharmaceuticals Inc. - San Diego (United States)

THEME

Clinical trials: cognitive and functional endpoints

RP4

Improving Screening Efficiency Through Alternate Story Recall

[Thomas Doherty](#) 1, Robert Smith 2, Michael Smith 3, Shau-Yu Lynch 4, Jeri Morris 5, Chad Swanson 4

1Worldwide Clinical Trials - London, England (United Kingdom), 2Worldwide Clinical Trials - Canet, France (United Kingdom), 3Worldwide Clinical Trials - Charlotte, Nc (United Kingdom), 4Eisai Inc. - Woodcliff Lake, Nj (USA), 5Roosevelt University Chicago - Chicago, Il (USA)

P6

Natural Disease Progression Model of Alzheimer's Disease Using the Integrated Alzheimer's

[Brian Willis](#) 1, Alette Wessels 1, Laiyi Chua 1, Kay Chow 1, Emmanuel Chigutsa 1, John Sims 1, Ivelina Gueorguieva 1

Eli Lilly And Company - Indianapolis (USA)

THEME

Clinical trials: imaging

RP5

Comparison of CT and MRI based standardized uptake value ratio for the amyloid PET analysis in subjective cognitive decline and mild cognitive impairment subjects

[Dong Won Yang](#) 1, Yun Jeong Hong 1, Junghee Cho 1, Young Chul Youn 1

Department Of Neurology, College Of Medicine, The Catholic University Of Korea - Seoul (Korea, Republic of)

RP6

Diagnostic performance for Alzheimer's Disease of the deep learning-based classification system using brain magnetic resonance imaging

[Bae Jong Bin](#) 1, Kim Ki Woong 1

Seoul National University Bundang Hospital - Seongnam-Si (Korea, Republic of)

● POSTERS presented remotely

- P18** **Mild behavioral impairment correlates of cognitive impairments in older adults without dementia: Mediation by amyloid pathology**
Yan Sun 1, Jintai Yu 2, Lan Tan 3
1Department Of Neurology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China. - Qingdao (China), 2Department Of Neurology And Institute Of Neurology, Huashan Hospital, State Key Laboratory Of Medical Neurobiology And Moe Frontiers Center For Brain Science, Shanghai Medical College, Fudan University, Shanghai, China. - Shanghai (China), 3Department Of Neurology And Institute Of Neurology, Huashan Hospital, State Key Laboratory Of Medical Neurobiology And Moe Frontiers Center For Brain Science, Shanghai Medical College, Fudan University, Shanghai, China. - Qingdao (China)
- LRP1bis** **Six Recurrent Amyloid Related Imaging Abnormality Episodes in a Patient Treated with Aducanumab BV 2 JT2**
Jacob Hall 1, Elizabeth Mormino 2, Amanda Ng 2, Athanasia Boumis 3, Jennifer Gaudio 4, Guido Davidzon 5, Sharon Sha 2
1The Neurology Center Of Southern California - Temecula (United States), 2Department Of Neurology And Neurological Sciences, Stanford University - Stanford (United States), 3Stanford Center For Clinical Research, Stanford University - Stanford (United States), 4Global Alzheimer's Platform Foundation - San Francisco (United States), 5Division Of Nuclear Medicine & Molecular Imaging, Department Of Radiology, Stanford University - Stanford (United States)
- LRP2bis** **In vivo 18F-APN-1607 tau PET/CT imaging of patients with frontotemporal lobar degeneration due to different MAPT mutations: Cross-sectional and longitudinal findings**
Xin-Yue Zhou 1, Jia-Ying Lu 1, Feng-Tao Liu 1, Chuan-Tao Zuo 1, Yi-Min Sun 1, Jian Wang 1
Huashan Hospital, Fudan University - Shanghai (China)

THEME

Clinical trials: biomarkers including plasma

- RP7** **Levels of circulating memory CD8 T cells that induce AD-like pathology in mice correlate with cognition and decreased CSF Aβ42 in patients**
Christopher Wheeler 1, 2, Debby Van Dam 3, 4, Yannick Vermeiren 3, 4, Hans De Reu 3, Peter Paul De Deyn 3, 4, Vicky Yamamoto 5, 2
1T-Neuro Pharma, Inc. - Aptos (USA), 2Brain Mapping Fndn. - Pacific Palisades (USA), 3University Of Antwerp - Antwerp (Belgium), 4University of Groningen - Groningen (Netherlands), 5University Of Southern California - Los Angeles (USA)
- RP8** **Serum Inflammatory biomarkers in Mild vs Moderate patients undergoing therapeutic plasma exchange with albumin replacement as a treatment for Alzheimer's disease**
Ana María Ortiz 1, Carla Minguet 1, Ricardo Gonzalo 1, Laura Núñez 1, Agustín Ruiz 2, 3, Oscar L López 4, Mercè Boada 2, 5, Antonio Páez 1, Montserrat Costa 1
1. grifols Bioscience Research - Barcelona (Spain), 2. research Center And Memory Clinic, Fundació Ace, Institut Català De Neurociències Aplicades-Universitat Internacional De Catalunya - Barcelona (Spain), 3. Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III - Madrid (Spain) - Madrid (Spain), 4. departments Of Neurology And Psychiatry, University Of Pittsburgh School Of Medicine - Pittsburgh (USA), 5. Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III - Madrid (Spain)
- RP9** **A polygenic risk score is associated with Alzheimer's brain pathology in an age-dependent manner**
Joseph Quinn 1, Chao-Yi Wu 1, Sahi Kolli 2, Nora Mattek 3, Randall Woltjer 3, Shawn Westaway 3, Jeffrey Kaye 3, Kelly Bakulski 4, Hiroko Dodge 4
1Department Of Neurology, Layton Aging And Alzheimer's Disease Center, Oregon Health & Science University - Portland (USA), 2International Business Machines (ibm) - New York (USA), 3Department Of Neurology, Layton Aging And Alzheimer's Disease Center, Oregon Health & Science University - Portland, Or (USA), 4Department Of Epidemiology At The University Of Michigan School Of Public Health And Michigan Alzheimer's Disease Center - Ann Arbor (USA)
- RP10** **Longitudinal Tau Accumulation in Alzheimer's disease: Prospective 5-year Follow-up Study**
Hanna Cho 1, Min Seok Baek 2, Han-Kyeol Kim 1, Jae Hoon Lee 3, Joong-Hyun Chun 4, Young Hoon Ryu 3, Chul Hyounng Lyoo 3
1Department Of Neurology, Gangnam Severance Hospital, Yonsei University College Of Medicine - Seoul (Korea, Republic of), 2Department Of Neurology, Wonju Severance Christian Hospital, Yonsei University Wonju College Of Medicine - Wonju (Korea, Republic of), 3Department Of Nuclear Medicine, Gangnam Severance Hospital, Yonsei University College Of Medicine - Seoul (Korea, Republic of), 4Department Of Nuclear Medicine, Severance Hospital, Yonsei University College Of Medicine - Seoul (Korea, Republic of)
- RP11** **Assessment of High Risk for Alzheimer's Disease Using Plasma Biomarkers in Subjects with Normal Cognition in Taiwan**
Shieh-Yueh Yang 1
Magqu Co., Ltd. - New Taipei City (Taiwan, Province of China)
- RP12** **Evidence of plasma biomarkers for high risk of dementia in cognitively normal subjects of post stroke, family history of Alzheimer's disease, diabetes mellitus, end-stage renal disease and obstructive sleep apnea**
Shieh-Yueh Yang 1
Magqu Co., Ltd. - New Taipei City (Taiwan, Province of China)
- RP13** **Dynamic changes of CSF sTREM2 in preclinical Alzheimer's disease: The CABLE study**
Lingzhi Ma 1
Department Of Neurology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China (China)
- RP13bis** **Cerebrospinal fluid platelet-derived growth factor receptor-β measured in BioFINDER 2: a marker of microvascular damage?**
Claudia Cicognola 1, 2, Shorena Janelidze 1, Danielle Van Westen 3, 4, Khazar Ahmadi 1, Oskar Hansson 1, 2
1Clinical Memory Research Unit, Lund University (Sweden), 2Memory Clinic, Skåne University Hospital (Sweden), 3Diagnostic Radiology, Department Of Clinical Sciences Lund, Lund University (Sweden), 4Image and Function, Skåne University Hospital, Malmö (Sweden)

● POSTERS presented remotely

- P21** **Plasma Neurofilament Light and Longitudinal Progression of White Matter Hyperintensity in Elderly Persons Without Dementia**
Yan Sun 1, Jintai Yu 2, Lan Tan 3
1Department Of Neurology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China. - Qingdao (China), 2Department Of Neurology And Institute Of Neurology, huashan hospital, Shanghai Medical College, Fudan University, Shanghai, China - Shanghai (China), 3Department Of Neurology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China - Qingdao (China)
- LRP3** **Pre-analytics of the A β 1-42/A β 1-40 ratio in fresh and frozen samples using an optimized CSF collection protocol**
Rianne Esquivel 1, Sara Ho 2, Jacqueline Darrow 2, Amanda Calabro 1, Sara Gannon 1, Parmi Thakker 2, Francesca De Simone 1, Abhay Moghekar 2
1Fujirebio Diagnostics Inc - Malvern (United States), 2Johns Hopkins School Of Medicine - Baltimore (United States)
- LRP4** **Pre-Analytical Effects of Cap Contact and Mixing on CSF A β 1-42, A β 1-40, and ptau181 Concentrations when Measured on an Automated Chemiluminescent Platform**
Sara Ho 1, Francesca De Simone 2, Jacqueline Darrow 1, Amanda Calabro 2, Parmi Thakker 1, Sara Gannon 2, Rianne Esquivel 2, Abhay Moghekar 1
1Johns Hopkins School Of Medicine - Baltimore (United States), 2Fujirebio Diagnostics Inc - Malvern
- LRP5** **Evaluate the Utility of Sapphire II Scanning Compared to Quantitative Beta Amyloid PET Scans in MCI and Mild AD Subjects**
Carl Sadowsky 1, Susanne Wilke 2, Suzanne Hendrix 3, Dennis Nilan 2
1Premier Neurology - West Palm Beach (United States), 2Cognoptix - Marlborough (United States), 3Pentara - Salt Lake City (United States)
- THEME**
Clinical trials: methodology
- RP14** **The ADataViewer: Exploring Alzheimer's Disease Cohort Data**
Yasamin Salimi 1, 2, Daniel Domingo-Fernández 1, Carlos Bobis-Álvarez 3, Martin Hofmann-Apitius 1, 2, Colin Birkenbihl 1, 2
1Department Of Bioinformatics, Fraunhofer Institute For Algorithms And Scientific Computing (scai) - Sankt Augustin (Germany), 2Bonn-Aachen International Center for IT, Rheinische Friedrich-Wilhelms-Universität Bonn - Bonn (Germany), 3University Hospital Ntra. Sra. De Candelaria - Santa Cruz De Tenerife (Spain)
- RP15** **What Might Intrinsic Changes in Screen to Baseline CDRs in Alzheimer's Clinical Trials Signify: An Exploratory Analysis**
Alan Kott 1, David Miller 2
1Signant Health - Prague (Czech Republic), 2Signant Health - Blue Bell (USA)
- RP15bis** **Optimization of clinical trial design for combination therapies using virtual patients**
Hugo Geerts 1, Mike Walker 2, Rachel Rose 2
1Certara - Berwyn, Pa (USA), 2Certara - Sheffield UK (United Kingdom)
- RP16** **Evaluating the effectiveness of a digital therapeutic to reduce Alzheimer's risk: A randomized controlled trial**
Mark Mcinnis 1, Richard Isaacson 2, Robert Krikorian 3
1Retain Health - Bedford (USA), 2Alzheimer's Disease Education Consultants - Miami Beach (USA), 3University Of Cincinnati Academic Health Center - Cincinnati (USA)
- RP17** **Clinical Trial Protocol of Bromocriptine in Alzheimer's Disease with Presenilin 1 (PSEN1) Mutations**
Haruhiko Banno 1, Takayuki Kondo 1, Taro Okunomiya 1, Yoko Amino 1, Akiyoshi Nakakura 1, Ryuji Uozumi 1, Harue Tada 1, Akihiro Shindo 2, Takakuni Maki 1, Manabu Ikeda 3, Yuishin Izumi 4, Kazutomi Kanemaru 5, Kenji Ishii 6, Kazue Shigenobu 7, Yoshihide Sunada 8, Toshifumi Watanabe 9, Osamu Uchikawa 10, Ryosuke Takahashi 1, Hidekazu Tomimoto 2, Haruhisa Inoue 1
1Kyoto University - Kyoto (Japan), 2Mie University - Tsu (Japan), 3Osaka University - Suita (Japan), 4Tokushima University - Tokushima (Japan), 5Tokyo Metropolitan Geriatric Medical Center - Tokyo (Japan), 6Tokyo Metropolitan Institute Of Gerontology - Tokyo (Japan), 7Asakayama Hospital - Sakai (Japan), 8Kawasaki Medical School - Kurashiki (Japan), 9Time Therapeutics, Inc. - Kyoto (Japan), 10Towa Pharmaceutical Co.,Ltd. - Osaka (Japan)
- P29** **Effects of Exclusion Criteria on Disease Modifying Clinical Trials for Alzheimer's Disease**
Aaron Ritter 1, Joel Adu-Brimpong 1, Marwan Sabbagh 1, Jiong Shi 1, Justin Miller 1, Jessica Caldwell 1
Cleveland Clinic - Las Vegas (USA)
- LRP6** **Impact of gender on the willingness to consider participating in clinical trials and undergo a lumbar puncture in middle aged individuals at risk of Alzheimer's disease**
Lidia Canals-Gispert 1, Alba Cañas-Martínez 1, Gema Huesa 1, Marc Suárez-Calvet 1, 2, 3, Marta Milà-Alomà 1, 2, 3, Eider Arenaza-Urquijo 1, 2, 3, Davide Cirillo 4, Annemarie Schumacher Dimech 4, 5, Maria Florencia Iulita 4, 6, Julie Martinkova 7, 4, Maria Carmela Tartaglia 4, Gonzalo Sánchez-Benavides 1, 2, 3, Carolina Minguiñón 1, 2, 3, Karine Fauria 1, 2, 3, Maria Teresa Ferretti 4, Anna Brugulat-Serrat 1, 2, 3
1Barceloneta Brain Research Center - Barcelona (Spain), 2MIM (Hospital del Mar Medical Research Institute) - Barcelona (Spain), 3Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES) - Madrid (Spain), 4Women's Brain Project - Guntershausen (Switzerland), 5Department of Health Sciences and Medicine, University of Lucerne - Lucerne (Switzerland), 6Sant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona - Barcelona (Spain), 7Cognitive Center, Department Of Neurology, Second Faculty Of Medicine, Charles University, And Motol University Hospital - Prague (Czech Republic)

● POSTERS presented remotely

- LRP7** **QyPredict®: added value to patient selection strategies and statistical analysis in clinical trials on Alzheimer's Disease**
Jorge Samper-Gonzalez 1, Marwan Sabbagh 2, Philippe Scheltens 3, Elizabeth Gordon 1, Antoine Movschin 1, Nicolas Guizard 1, Clarisse Longo Dos Santos 1, Enrica Cavedo 1, Alireza Atri 4, 5, Bruno Dubois 6
1Oynapse - Paris (France), 2Cleveland Clinic Lou Ruvo Center For Brain Health - Las Vegas, Nv (United States), 3Amsterdam University Medical Center - Amsterdam (Netherlands), 4Banner Sun Health Research Institute, Banner Health - Sun City, Az (United States), 5Brigham and Women's Hospital, Harvard Medical School - Boston, Ma (United States), 6Institute Of Memory And Alzheimer's Disease (im2a), Centre Of Excellence Of Neurodegenerative Disease (coen), Icm, Cic Neurosciences, Ap-Hp, Department Of Neurology, Hôpital De La Pitié-Salpêtrière, Sorbonne University - Paris (France)
- LRP8** **A Fully Virtual Trial Design in Times of COVID-19: Early Lessons Learned from the REACTION study in Age-Related Cognitive Decline**
Christian Camargo 1, Katalina Mcinerney 1, Danielle Counotte 2, Tatjana Rundek 1
1University Of Miami Miller School Of Medicine - Miami (United States), 2Danone Nutricia Research - Utrecht (Netherlands)
- LRP9** **An assessment of the statistical reliability of data-driven decomposition for the use of multi-modal analyses**
Kristen Knight 1, 2, Nicole Lazar 3, Liang Liu 4
1UCSF Department of Radiology and Biomedical Imaging - San Francisco, CA (United States), 2VA Advanced Imaging Research Center, San Francisco Veteran's Administration Medical Center - San Francisco, Ca (United States), 3PennState Department of Statistics - University Park, PA (United States), 4UGA Department of Statistics - Athens, GA (United States)

THEME Clinical trials: results

- RP18** **Fortasyn Connect's long-term intervention effects on Clinical Dementia Rating – sum of boxes and on memory in the LipiDiDiet RCT**
Tobias Hartmann 1, 2, Alina Solomon 3, 4, 5, Pieter Visser 6, 7, Suzanne Hendrix 8, Kaj Blennow 9, 10, Miia Kivilehto 3, 4, 5, Hilikka Soininen 3, 11
1Deutsches Institut Für Demenz Prävention (didp), Medical Faculty, Saarland University - Homburg (Germany), 2Department of Experimental Neurology, Saarland University - Homburg (Germany), 3Department Of Neurology, Institute Of Clinical Medicine, University Of Eastern Finland - Kuopio (Finland), 4Department of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet - Huddinge (Sweden), 5Clinical Trials Unit, Theme Aging, Karolinska University Hospital - Huddinge (Sweden), 6Department Of Psychiatry And Neuropsychology, Alzheimer Centre Limburg, University Of Maastricht - Maastricht (Netherlands), 7Department of Neurology, Alzheimer Centre, Amsterdam Neuroscience, VU University Medical Center - Amsterdam (Netherlands), 8Pentara Corporation - Millcreek (USA), 9Department Of Psychiatry And Neurochemistry, Institute Of Neuroscience And Physiology, The Sahlgrenska Academy At University Of Gothenburg - Mölndal (Sweden), 10Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital - Mölndal (Sweden), 11Neurocentre, Department of Neurology, Kuopio University Hospital - Kuopio (Finland)
- RP19** **Validation of exposure-dependent activity on cognitive and functional decline confirms hydromethylthionine as a potential near-term oral treatment for Alzheimer's disease (AD)**
Claude Wischik 1, 2, Helen Shiells 1, Bjoern Schelter 1, 2
1Taurx Therapeutics Ltd - Aberdeen (United Kingdom), 2University of Aberdeen - Aberdeen (United Kingdom)
- P41** **Single and multiple ascending dose studies in healthy volunteers to assess the safety and PK of LY3372689, an inhibitor of the O-GlcNAcase (OGA) enzyme**
Paul Goldsmith 1, Stephen Lowe 1, Krista Phipps 1, Kevin Donnelly 1, Kevin Biglan 1, Michele Mancini 1, Hugh Nuthall 1, Dustin J. Mergott 1, William Kielbasa 1
Eli Lilly And Company, Lilly Corporate Center - Indianapolis (USA)
- P43bis** **Brain target occupancy of LY3372689, an inhibitor of the O-GlcNAcase (OGA) enzyme, following administration of single and multiple doses to healthy volunteers**
William Kielbasa 1, Sergey Shcherbinin 1, Paul Goldsmith 1, Krista M. Phipps 1, Kevin Biglan 1, Michele Mancini 1, David Russell 2, Cristian Constantinescu 2, Roger N. Gunn 3, Hugh N. Nuthall 1, Dustin J. Mergott 1, Stephen Lowe 1, Emily C. Collins 1
1Eli Lilly And Company, Lilly Corporate Center - Indianapolis (USA), 2Inivcro, A Konica Minolta Company New Haven - Connecticut (USA), 3Inivcro, A Konica Minolta Company, Burlington Danes Building, Imperial College London, Hammersmith Hospital, Du Cane Road - London (United Kingdom)
- P44** **ACI-24, an anti-beta amyloid vaccine, in patients with mild Alzheimer's disease: Results of a phase 2, randomized, double-blind, placebo-controlled study**
Olivier Sol 1, Saskia Delpretti 1, Marija Vukicevic 1, Merja Hallikainen 2, Roy Jones 3, Anne Börjesson-Hanson 4, Aliya Asher 5, Alex Thompson 6, Christopher Kipps 7, Emer Mcsweeney 8, Tanja Touilloux 1, Julian Gray 1, Nicolas Fournier 1, Valérie Hliva 1, Antonio Melo Dos Santos 1, Mika Scheinin 9, 10, Marie Kosco-Vilbois 1, Johannes Streffer 1, 11, Andrea Pfeifer 1, Juha Rinne 9, 10
1Ac Immune Sa - Lausanne (Switzerland), 2University Of Eastern Finland - Kuopio (Finland), 3University Of Bath - Bath (United Kingdom), 4Karolinska University Hospital - Stockholm (Sweden), 5Mac Clinical Research - Manchester (United Kingdom), 6Mac Clinical Research - Cannock (United Kingdom), 7Southampton General Hospital - Southampton (United Kingdom), 8Cognition Health Ltd. - Guildford (United Kingdom), 9University Of Turku - Turku (Finland), 10CRST Oy - Turku (Finland), 11Department of Biomedical Sciences, University of Antwerp - Antwerp (Belgium)
- LRP10** **Beneficial Effects of Masupirdine on Agitation in Patients with Alzheimer's disease: A Novel Non-sedating Mechanism**
Ramakrishna Nirogi 1, Anil Shinde 1, Abdul Rasheed Mohammed 1, Vinod Kumar Goyal 1, Santosh Kumar Pandey 1, Vijay Benade 1, Veera Raghava Chowdary Palacharla 1, Ramkumar Subramanian 1, Renny Abraham 1, Pradeep Jayarajan 1, Jyothsna Ravula 1, Satish Jetta 1
Suven Life Sciences Ltd - Hyderabad (India)

● POSTERS presented remotely

THEME

Cognitive assessment and clinical trials

- RP20 Association between a computerized, self-administered cognitive assessment and fluid biomarkers of neurodegeneration**
Mina Aghaei 1, Mohammad Hadi Modarres 2, Zahra Vahabi 3, 4, Chris Kalafatis 5, 6, 7, Haniye Marefat 8, Mahdie Khanbagi 1, Hamed Karimi 9, 1, Seyed-Mahdi Khaligh-Razavi 2, 1
1Royan Institute For Stem Cell Biology And Technology, Acecr - Tehran (Iran, Islamic Republic of), 2Cognetivity Ltd - London (United Kingdom), 3Department Of Geriatric Medicine, Ziaei Hospital, Tehran University Of Medical Sciences - Tehran (Iran, Islamic Republic of), 4Memory and Behavioral Neurology Division, Roozbeh Hospital, Tehran University of Medical Sciences - Tehran (Iran, Islamic Republic of), 5South London & Maudsley Nhs Foundation Trust - London (United Kingdom), 6Department of Old Age Psychiatry, King's College London - London (United Kingdom), 7Cognetivity Ltd - London (United Kingdom), 8School Of Cognitive Sciences, Institute For Research In Fundamental Sciences (ipm) - Tehran (Iran, Islamic Republic of), 9Department Of Mathematics And Computer Science, Amirkabir University Of Technology - Tehran (Iran, Islamic Republic of)
- RP21 The development of ObsRVR: an Observational Instrument to measure Reactions of People with Dementia Experiencing Virtual Reality**
Lora Appel 1, Erika Kisonas 2, Eva Appel 2
1York University - Toronto (Canada), 2University Health Network - Toronto (Canada)
- RP22 Psychometric validation of the Brief And Simple Index of Cognition (BASIC) and sensitivity to cognitive impairment in individuals living with MCI and Alzheimer's disease**
Anna Barczak 1, Sebastian Harrison 2, Ninoslav Mimica 3, John Harrison 4
1Mossakowski Medical Research Centre - Warszawa (Poland), 2Manchester Metropolitan University - Manchester (United Kingdom), 3University Psychiatric Hospital Vrapce - Zagreb (Croatia), 4Metis Cognition Ltd - Kilmington (United Kingdom)
- RP23 Tau pathologies mediate the association of blood pressure with cognitive impairment in adults without dementia: The CABLE study**
Hu Hao 1, Tan Lan 1, Yu Jin-Tai 2
1Qingdao University - Qingdao (China), 2Fudan University - Shanghai (China)
- RP24 Identification of novel drug targets for Alzheimer's disease by integrating genetics and proteomes from brain and blood**
Jin-Tai Yu 1
Department Of Neurology And Institute Of Neurology, Huashan Hospital, State Key Laboratory Of Medical Neurobiology And Moe Frontier Center For Brain Science, Shanghai Medical College, Fudan University - Shanghai (China)
- RP25 Sigmoid methodology allows early prediction of cognitive decline towards Alzheimer's disease across several cognitive domains**
Marcela Cespedes 1, Cai Gillis 2, Paul Maruff 3, 4, Nancy Maserejian 2, Chris Fowler 5, Stephanie Rainey-Smith 6, 7, Victor Villemagne 8, 9, Christopher Rowe 5, 10, Ralph Martins 7, 9, 11, Colin Masters 5, James Doecker 1
1Australian E-Health Research Centre, Csiro - Herston, Qld (Australia), 2Biogen - Cambridge, Ma (USA), 3Cogstate Pty. Ltd - New Haven, Ct (USA), 4University of Melbourne - Parkville, Vic (Australia), 5The Florey Institute Of Neuroscience And Mental Health, University Of Melbourne - Parkville, Vic (Australia), 6Centre For Healthy Ageing, Health Futures Institute, Murdoch University - Murdoch, Western Australia (Australia), 7Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University - Joondalup, Western Australia (Australia), 8Department Of Molecular Imaging And Therapy, Austin Health - Heidelberg, Victoria (Australia), 9Department of Psychiatry, The University of Pittsburgh - Pittsburgh, Pa (USA), 10Department of Biomedical Sciences, Faculty of Medicine, Health and Human Sciences, Macquarie University - Sydney, New South Wales (Australia), 11Sir James McCusker Alzheimer's Disease Research Unit (Hollywood Private Hospital) - Perth, Western Australia (Australia)
- P55 Evaluation relationships between subjective wellbeing, personality traits, and Alzheimer's disease: A two-sample Mendelian randomization study**
Ya-Hui Ma 1, Yu-Xiang Yang 2, Qiang Dong 2, Lan Tan 3, Jin-Tai Yu 2
1Qingdao Municipal Hospital, College Of Clinical Medicine, Qingdao University - Qingdao (China), 2Fudan University - Shanghai (China), 3Qingdao Municipal Hospital, College Of Clinical Medicine, Qingdao University - Shanghai (China)
- P56 Serum uric acid may aggravate Alzheimer's disease risk by affecting amyloidosis in cognitively intact older adults: The CABLE study**
Lin-Lin Li 1, Ya-Hui Ma 2, Jin-Tai Yu 3
1Dalian Medical University - Dalian (China), 2Qingdao Municipal Hospital, College of Clinical Medicine, Qingdao University - Qingdao (China), 3Fudan University - Shanghai (China)
- P60 Metabolically healthy obesity and lipids may be protective factors for pathological changes of Alzheimer's disease in cognitively normal adults**
Shu-Juan Huang 1, Ya-Hui Ma 1, Lan Tan 1, Jin-Tai Yu 2
1Qingdao Municipal Hospital, Qingdao University - Qingdao (China), 2Fudan University - Shanghai (China)

● POSTERS presented remotely

THEME

Epidemiology and clinical trials

- RP34** Association of body mass index with risk of cognitive impairment and dementia: A systematic review and meta-analysis of prospective studies
Yi Qu 1, Lan Tan 1, Jintai Yu 2
1Department Of Neurology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China - Qingdao (China), 2Department Of Neurology And Institute Of Neurology, Huashan hospital, Shanghai Medical College, Fudan University, Shanghai, China - Shanghai (China)
- RP35** Modifiable Risk Factors for Incident Dementia and Cognitive Impairment: An Umbrella Review of Evidence
Jin-Tai Yu 1
Department Of Neurology and Institute Of Neurology, Huashan Hospital, State Key Laboratory Of Medical Neurobiology And Moe Frontiers Center For Brain Science, Shanghai Medical College, Fudan University - Shanghai (China)
- RP36** Global prevalence of Alzheimer's disease across disease stages
Anders Gustavsson 1, Nicholas Norton 2, Thomas Fast 2, Lutz Frölich 3, Drew Holzapfel 4, Tunahan Kirabali 5, Pierre Krolak-Salmon 6, Paolo Maria Rossini 7, Lydia Lanman 8, Antonella Santucci Chadha 5, Wiesje M. Van Der Flier 9
1Quantify Research; Department Of Neurobiology, Care Sciences And Society, Karolinska Institute - Stockholm (Sweden), 2Quantify Research - Stockholm (Sweden), 3Department Of Geriatric Psychiatry, Central Institute Of Mental Health Medical Faculty Mannheim, University Of Heidelberg - Mannheim (Germany), 4Ceo Initiative On Alzheimer's Disease - Philadelphia (USA), 5Biogen - Baar (Switzerland), 6Lyon Institute For Elderly, Clinical & Research Memory Center Of Lyon - Lyon (France), 7Faculty Of Medicine Of The Catholic University Of The Sacred Heart; Neuroscience Area Of Policlinico Foundation A. Gemelli - Rome (Italy), 8F. Hoffmann-La Roche - Basel (Switzerland), 9Alzheimer Center Amsterdam, Department Of Neurology, Department Of Epidemiology And Data Science, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam Umc - Amsterdam (Netherlands)
- RP37** Association between Widespread Pain and Dementia, Alzheimer's disease and Stroke: A Cohort Study from the Framingham Heart Study
Kanran Wang 1
The First Affiliated Hospital of Chongqing Medical University - Chongqing (China)
- RP38** Genetically determined blood pressure, antihypertensive medications, and risk of Alzheimer's disease: a Mendelian randomization study
Ya-Nan Qu 1, Lan Tan 1, Jin-Tai Yu 2
1Department Of Neurology, Qingdao Municipal Hospital, Qingdao University - Qingdao (China), 2Department Of Neurology And Institute Of Neurology, Who Collaborating Center For Research And Training In Neurosciences, Huashan Hospital, Shanghai Medical College, Fudan University - Shanghai (China)
- P62** Social Networks and Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Pathology in Cognitively Intact Older Adults: The CABLE Study
Ya-Hui Ma 1, Ya-Yu Wang 2, Lan Tan 3, Jin-Tai Yu 4
1Qingdao Municipal Hospital, College of Clinical Medicine, Qingdao University - Qingdao (China), 2Qingdao Municipal Hospital, College of Clinical Medicine, Dalian Medical University - Dalian (China), 3Qingdao Municipal Hospital, College of Clinical Medicine, Dalian Medical University - Qingdao (China), 4Fudan University - Shanghai (China)

THEME

Digital health/E-trials

- RP26** Evaluation of efficacy and cost-effectiveness of promotions for recruiting online participants to Japanese Trial-Ready Cohort (J-TRC) study
Kenichiro Sato 1, Yoshiki Niimi 2, Ryoko Ihara 3, Kazushi Suzuki 4, Atsushi Iwata 3, Takeshi Iwatsubo 1
1University Of Tokyo - Bunkyo City (Japan), 2University Of Tokyo Hospital - Bunkyo City (Japan), 3Tokyo Metropolitan Geriatric Medical Center Hospital - Itabashi City (Japan), 4National Defense Medical College - Tokorozawa City (Japan)
- RP27** Decision-Making and Reactions on Genetic Testing in Alzheimer's Disease among Patients, Caregivers, and Healthcare Professionals
Amir Tahami 1, Stephen Doogan 2, Nardin Farid 2, Margaret Bray 1, Esra Karahan 1, Quanwu Zhang 1
1Eisai - Woodcliff Lake, NJ (USA), 2Real Life Sciences - King Of Prussia, PA (USA)
- RP28** Amyloid Prediction in Early-Stage Alzheimer's Disease From Acoustic and Linguistic Patterns of Speech: design of the AMYPRED studies
Emil Fristed 1, Marton Meszaros 1, Caroline Skirrow 1, Jack Weston 1
Novoic - London (United Kingdom)
- RP29** A Multi-modal Curriculum on Dementia-related Psychosis for the Public: A Randomized Trial
Nabeel Saif 1, Kellyann Niotis 1, Ciara Gaglio 1, Richard Isaacson 1
Weill Cornell Medicine - New York (USA)
- RP30** Comparison of the accuracy of Cogniciti's self-administered, online, Brain Health Assessment to the Montreal Cognitive Assessment in detecting amnesic mild cognitive impairment
Theone Paterson 1,2, Brintha Sivajohan 3, Sandra Gardner 4, Malcolm Binns 5, Kathryn Stokes 2, Morris Freedman 6,5,7, Brian Levine 5,8, Angela Troyer 2
1University Of Victoria - Victoria (Canada), 2Baycrest Health Sciences Centre - Toronto (Canada) - Toronto (Canada), 3Western University - London (Canada), 4Baycrest Health Sciences Centre - Toronto (Canada), 5Rotman Research Institute - Toronto (Canada), 6Baycrest Health Sciences Centre-Toronto (Canada) - Toronto (Canada), 7Toronto Dementia Research Alliance - Toronto (Canada), 8University of Toronto - Toronto (Canada)

● POSTERS presented remotely

RP31 **“ComuniChiAmo”: an e-Health pilot study for the development of a community support network for carers of people with dementia**
Cristina Festari 1, Stefania Orini 2, Anna Mega 1, Cristina Muscio 3, Pietro Tiraboschi 3, Marco Trabucchi 4, 5, Orazio Zanetti 2, Rabih Chattat 6
1Laboratory Of Alzheimer's Neuroimaging And Epidemiology At The Istituto Centro San Giovanni Di Dio Fatebenefratelli (Italy) - Brescia (Italy), 2Ircs Istituto Centro San Giovanni Di Dio Fatebenefratelli, Brescia, Italy - Brescia (Italy), 3Neurology 5-Neuropathology Unit, Fondazione Irccs Istituto Neurologico Carlo Besta, Italy - Milan (Italy), 4Department Of Pharmacology, Tor Vergata University, Rome, Italy - Rome (Italy), 5 Associazione Italiana di Psicogeriatría, Brescia, Italy - Brescia (Italy), 6Department Of Psychology, University Of Bologna, Bologna, Italy. - Bologna (Italy)

RP32 **VRCT: Randomized Controlled Trial Evaluating the Impact of Virtual Reality-therapy on BPSD and QoL of Acute Care In-patients With Dementia**
Lora Appel 1, Eva Appel 2, Erika Kisona 2, Jarred Rosenberg 3, Julian Appel 4, Christopher Smith 3
1York University - Toronto (Canada), 2University Health Network - Toronto (Canada), 3Michael Garron Hospital - Toronto (Canada), 4Ryerson University - Toronto (Canada)

LRP12 **Remote actigraphy measurement with a simple-to-use wearable device: Feasibility and compliance in older adults with and without subjective cognitive decline**
Michael Kraus 1, Alexandra Atkins 1, William Horan 1, Heather Stevens 1, Erica Walton 1, Joshua Yuan 1, Matthew Welch 1, Haley Evans 1, Richard Keefe 1
Verasci - Durham (United States)

LRP13 **A Machine Learning Based Multi-modal Imaging Genetic Study to Predict Future Progression and Conversion to Alzheimer's Disease**
Ghazal Mirabnahrain 1, Da Ma 1, Sieun Lee 1, 2, Karteek Popuri 1, Hyunwoo Lee 3, Jiguo Cao 1, Lei Wang 4, James E Galvin 5, Mirza Faisal Beg 1
1Simon Fraser University - Burnaby (Canada), 2University Of Nottingham - Nottingham (United Kingdom), 3University Of British Columbia - Vancouver (Canada), 4Ohio State University Wexner Medical Center - Columbus (United States), 5University Of Miami Miller School Of Medicine - Miami (United States)

THEME

Health economics and clinical trials

RP33 **Using ARIA to detect cognitive normal subjects with high burden WMH for early prevention clinical trials of dementia – suggestions based on a simulation trial**
Jianlin Liang
Chinese University of Hong Kong, Hong Kong (China)

LRP11 **Impact of physical activity on cognitive decline in adults: A FLAME analysis in the PROTECT cohort**
Helen Brooker 1, Vincent Hayman 1, Dag Aarsland 2, Byron Creese 1, Clive Ballard 1, Anne Corbett 1
1Exeter University Medical School - Exeter (United Kingdom), 2Department Of Old Age Psychiatry, Institute Of Psychiatry, Psychology & Neuroscience, Maurice Wohl Clinical Neuroscience Institute, King's College London, London, Uk - London (United Kingdom)

THEME

New therapies and clinical trials

RP39 **Alpha-1 antitrypsin variants and obstructive sleep apnea: practical targets for modulating inflammation and altering trajectory of MCI/dementia**
Donald Schmechel 1
AcrossAlpha; Neurology Specialists Of Charleston - Burnsville

RP40 **A randomized, placebo-controlled, double-blind, single ascending dose study to evaluate the safety, tolerability and pharmacokinetics of a subcutaneous organ-spondin-derived peptide in healthy volunteers**
Valérie Bourdès 1, Peter Dogterom 2, Pierre Parmantier 3, Damien Colas 3, Sighild Lemarchant 1, Sébastien Marie 1, Khalid Abd-Elaziz 2, Yann Godfrin 4
1Axoltis - Lyon (France), 2QPS Netherlands B.V - Groningen (Netherlands), 3Athena Bio Consulting - Lyon (France), 4Godfrin Life Sciences - Caluire-et-Cuire (France)

RP41 **Microdose Study of a Novel Psychostimulant Prodrug, PRX-P4-003, with Reduced Abuse Liability for Apathy in AD**
William Ziegler Potter 1, Valentino Stella 1, 2, Sandeep Patil 1
1Praxis Bioresearch - Sacramento (USA), 2University of Kansas - Lawrence (USA)

● POSTERS presented remotely

THEME

Proof of concept/Translational research for Alzheimer Drug Development interventions

RP42 Inhibition of the equilibrative nucleoside transporter 1 (ENT1) rescues cognitive impairment and misfolded protein accumulation in two mouse models with distinct features of Alzheimer's disease pathology

Ching-Pang Chang 1, 2, Chien-Yu Lin 1, 2, Kuo-Chen Wu 2, Hsin-Hsien Yeh 3, Chun-Jung Lin 4, Yijuang Chern 1, 2

1Institute of Biomedical Sciences, Academia Sinica - Taipei (Taiwan, Province of China), 2Biomedical Translation Research Center, Academia Sinica - Taipei (Taiwan, Province of China), 3Brain Research Center, National Yang Ming Chiao Tung University - Taipei (Taiwan, Province of China), 4School Of Pharmacy, National Taiwan University - Taipei (Taiwan, Province of China)

RP43 Targeting microRNA-485-3p blocks Alzheimer's disease progression

Hanseok Koh 1, Sangjoon Lee 2, Hyojin Lee 1, Jaewoong Min 1, Takeshi Iwatsubo 3, Charlotte Teunissen 4, Hyunjeong Cho 5, Jinhyeob Ryu 6

1Biorchestra Co., Ltd. - Daejeon (Korea, Republic of), 2University Of Tsukuba - Ibaraki (Japan), 3University Of Tokyo - Tokyo (Japan), 4Amsterdam Umc, VU University - Amsterdam (Netherlands), 5College Of Medical Science, Konyang University - Daejeon (Korea, Republic of), 6Biorchestra Co., Ltd. - Boston (USA)

LRP14 Investigating potential druggability of long non-coding RNAs for novel treatment of Alzheimer's Disease

Yuji Zhang 1, Cui Tao 2

1University Of Maryland Baltimore - Baltimore (United States), 2University Of Texas Health Science Center - Houston (United States)

CTAD would like to thank its 2021 Gold partners for their continued support



The logo features the letters 'CTAD' in a large, bold, blue font. The 'A' is stylized with a globe pattern. To the right of 'CTAD', the word 'Alzheimer' is written vertically in a smaller font. Below 'CTAD', the year '2022' is displayed in a white box with a blue border.

CTAD Alzheimer 2022

Clinical Trials on Alzheimer's Disease

November 29 - December 2, 2022
San Francisco, USA

Montpellier '08 / Las Vegas '09 / Toulouse '10 / San Diego '11
Monte Carlo '12 / San Diego '13 / Philadelphia '14 / Barcelona '15
San Diego '16 / Boston '17 / Barcelona '18 / San Diego '19 / Virtual '20 / Boston '21

www.ctad-alzheimer.com

Email: ctad@ant-congres.com

